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Abstract 
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, and 
one that is generally amenable to surgical treatment when surgery is 
necessary. Unfortunately, roughly 25-30% of the patient population have no 
visible lesions on clinical MRI scans. Without anatomical abnormalities to 
help guide surgical resection, the success of surgical treatment decreases 
substantially. However, metabolic abnormalities may exist that could allow 
for accurate localization of epileptic tissue in this cohort. Magnetic resonance 
spectroscopy (MRS) is a technique that can detect and measure the 
concentration of metabolically important molecules within tissue, giving 
insight into the underlying cellular metabolism. 
In this thesis, non-lesional TLE patients were studied and compared with 
control subjects using single voxel MRS at a magnetic field strength of 7T for 
the first time. We hypothesized that metabolite changes in the hippocampus 
would be associated with seizure lateralization. Non-lesional patients showed 
altered levels of creatine and choline when compared to healthy controls. 
These results were in agreement with prior work in the literature showing 
non-lesional TLE is primarily a result of glial cell proliferation without 
neuronal atrophy. However, in the patient cohort studied, these metabolites 
did not effectively lateralize seizure origin, potentially due to the varied 
underlying pathologies within the patient group. 
Keywords: Epilepsy, Temporal Lobe Epilepsy, Magnetic Resonance 
Spectroscopy, Magnetic Resonance Imaging, 7T, Choline 
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Introduction 
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1.1 Research Motivation and Objectives 
The motivation for the work presented in this thesis was to improve surgical 
outcomes for patients with drug resistant temporal lobe epilepsy and normal 
appearing clinical MRI scans. In drug resistant epilepsy, surgical removal of 
seizure forming tissue is the most common method of treatment. However 
localization of seizure focus is often difficult in patients without visible 
disease markers on MRI, due to the poor localization abilities of other 
techniques such as electroencephalography (EGG) and clinical semiology. 
Uncertainty in the location of seizure origin has been shown to reduce the 
success rate of epilepsy surgery, largely because some seizure forming tissue 
can be missed in the resection. To address this issue, magnetic resonance 
spectroscopy (MRS) was explored in this thesis as a technique to non-
invasively identify and localize epileptic tissue in pre-surgical planning. 
Metabolite changes measured by MRS are indicative of altered tissue 
metabolism, and may be changed by seizure activity in the absence of MRI 
visible lesions. These MRS measurements were performed in this patient 
population for the first time at a magnetic field strength of 7T, with the goal 
of demonstrating that additional information can be gleaned from these 
measurements at 7T and to establish the clinical utility of the method.  
1.2 Epilepsy 
Epilepsy is described by the International League Against Epilepsy as, “… A 
diverse family of disorders, having in common an abnormally increased 
predisposition to seizures.” [1] Seizures themselves are transient events 
where neurons within the cortex begin firing out of control in a highly 
synchronous manner. The outward manifestations of a seizure vary 
dramatically from patient to patient based on where in the brain a seizure 
starts and how the seizure spreads throughout the cortex. These outward 
manifestations include potential symptoms such as behavioural arrest, loss of 
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consciousness, mood changes, and uncontrolled muscle contractions or 
spasms. Seizures can have a particularly devastating effect on a patient’s 
quality of life as loss of awareness and/or bodily control at unpredictable 
times robs many patients of their ability to function independently [1]. 
Furthermore, epilepsy is associated with a wide range of long term effects 
and comorbidities such as cognitive deficits (especially memory deficits) and 
mood disorders such as depression [2], [3]. Those with epilepsy are also at a 
significantly increased risk for sudden unexpected death (SUDEP) [4], and 
they are at risk for developing status epilepticus; a condition where the 
brain’s inhibitory mechanisms cannot bring a seizure under control, leading 
to a prolonged seizure that can cause permanent brain damage or death [5]. 
From a clinical perspective, epilepsy is commonly divided into two subtypes, 
focal and generalized epilepsy. Focal epilepsy describes a condition where a 
patient’s seizures consistently arise from specific unilateral regions within 
the brain, whereas generalized epilepsy describes patients where the seizure 
onset involves activation of large regions in both hemispheres simultaneously 
[6]. Within this classification scheme, temporal lobe epilepsy (TLE) is the 
most common form of focal epilepsy [7]–[9].  
1.2.1     The Temporal Lobe 
The temporal lobe is one of the primary divisions of the cerebrum; it lies near 
the base of the skull beneath the Sylvan fissure (Figure 1.1). The temporal 
lobes are functionally important for their role in the consolidation of memory 
and in forming speech. In the study of epilepsy, the mesial temporal lobe is 
particularly important (Figure 1.2). This region consists of a folded grey 
matter structure known as the hippocampus and nearby regions of cortical 
grey matter within the hippocampal gyrus. It receives highly processed 
sensory information from many disparate regions of the brain, and is 
responsible for consolidating working memory into long-term declarative 
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memory (facts and experiences). The mesial temporal lobe is the most 
common site of origin for temporal lobe seizures. Hippocampal sclerosis 
(hardening and atrophy of the hippocampus) has been the most common 
cause of epilepsy in this patient group; over 57% of patients with drug-
resistant TLE have clear hippocampal sclerosis on MRI (Figure 1.3) [10]–[12].  
1.2.2     Neurotransmission 
To understand epilepsy and the pathophysiology involved, it is important to 
understand the basic construction of the central nervous system (CNS). The 
two primary cell types composing the CNS are neurons and glial cells [10]. 
1.2.2.1     Neurons 
Neurons are the fundamental building blocks of the nervous system. A 
neuron is composed of a main cell body with numerous branches of varying 
lengths extending from this central core (Figure 1.4). Typically, a neuron will 
have a single main branch extending off the cell body, termed the axon, and 
numerous smaller branches, termed dendrites. Neurons receive a 
combination of electrical and/or chemical signals through interfaces across its 
surface called synapses, and transmit information away from the cell body 
along the axon, which in turn is connected to other neurons. When describing 
the transmission of signals between two neurons, a neuron that is sending 
signals are often referred to as the pre-synaptic neuron, while the neuron 
receiving signal from the pre-synaptic neuron is referred to as the post-
synaptic neuron. 
Neurons come in a wide range of shapes and sizes based on their function. 
Neurons used to connect the central nervous system to distant anatomical 
regions can be over a metre in length, while neurons within different parts of   
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Figure 1.1 - Lobes of the Human Brain  
Image by Henry Vandyke Carter and Henry Gray [13] [Public Domain], accessed via 
Wikimedia Commons 
 
 
Figure 1.2 - Anatomy of the Mesial Temporal Lobe  
Image by Dr. Johannes Sobotta [14] [Public Domain], accessed via Wikimedia Commons 
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Figure 1.3 – T1- and T2-weighted Images of Hippocampal Sclerosis: Image showing T2-
weighted (A) and T1-weighted (B) images of an epileptic patient with unilateral right 
hippocampal sclerosis (arrow). Note the increase in T2 signal, tissue atrophy, and loss of 
internal structure in the sclerotic hippocampus as compared to the healthy contralateral 
hippocampus.  
 
Image by K. Ganesan and M. Ursekar [15], [Licensed for non-commercial use under CC-BY-
NC-SA 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/)], accessed via the Indian 
Journal of Radiology and Imaging 
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Figure 1.4 - Labeled Diagram of 
a Neuron 
 
Image by Nicholas Rougier 
[Licensed under CC-BY-SA 3.0 
(http://creativecommons.org/licenses/
by-sa/3.0)], accessed via Wikimedia 
Commons 
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the CNS take on varied configurations. Throughout the body, neurons are 
networked together to form neural circuits that can store and process 
information [10]. 
1.2.2.2     The Action Potential 
A neuron is able to convey information along its length in the form of an 
electrical signal known as the action potential. The action potential itself is 
generated by the neuron selectively allowing aqueous sodium, calcium and 
potassium ions (Na+, Ca2+, and K+) from the surrounding environment to 
diffuse into or out of the cell, creating an electric current that propagates 
along the cell. Once the action potential reaches a synapse with another cell 
it can be transmitted between neurons through a number of different 
mechanisms. 
Prior to the beginning of an action potential, a neuron maintains a ‘resting 
potential’ of -65 mV. It is able to maintain this potential due to the action of 
ion pumps embedded within the cell membrane that selectively pump sodium 
and calcium ions out of the cell while pumping potassium ions into the cell. 
This creates concentration gradients that are exploited to generate the action 
potential. As other neurons send signals to a neuron, they transfer positively 
charged ions to the dendrites of the post-synaptic neuron. This transfer of 
charge is accomplished either by directly allowing ions to flow between cells 
through protein channels which bridge the synaptic cleft, or via the release of 
chemical signalling molecules known as neurotransmitters which open ion 
channels on the post-synaptic cell. 
Once the local cell membrane reaches a potential of -40 mV, voltage gated 
sodium channels on the post-synaptic membrane open, allowing a large influx 
of positively charged Na+ ions to diffuse into the cell. These channels remain 
open for ~1 ms before closing and locking shut. As the membrane continues to 
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depolarize, voltage gated potassium channels open allowing K+ to rapidly 
diffuse out of the cell, repolarizing the membrane until it is slightly more 
negative than the resting potential. With both the sodium and potassium 
channels closed, the aforementioned sodium-potassium pumps on the cell 
membrane can restore ion concentrations both within and outside the cell to 
their original state. This process creates the action potential waveform. An 
action potential takes about 2 ms to play out, followed by 1 ms refractory 
period during which the voltage-gated channels are locked closed and the 
neuron cannot fire. As the cell membrane goes through this firing cycle on the 
dendrites, it changes the electric potential of the surrounding membrane 
causing it to also undergo this process. In this way, the action potential 
travels from the dendrites, through the cell body, to the connection between 
the neuronal cell body and the axon, known as the axonal hillock. This region 
of the neuron acts as a signal integrator, collecting all signals received by the 
dendrites and cell body. If the sum total of all signals received by the neuron 
are enough to depolarize the axonal hillock, it will generate an action 
potential which will propagate down the axon and be transmitted to 
downstream neurons [10], [16]. 
It is worth noting that the process for generating an action potential 
described above simply covers neurotransmission between two neurons. 
Many specialized types of neurons, particularly in sensory organs such as the 
eyes or skin, can generate an action potential through a variety of 
mechanisms beyond what is described above. That said, all neurons 
communicate using action potentials, regardless of the means used to 
generate them [10]. 
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1.2.2.3 Excitation and Inhibition 
Neural circuits contain both excitatory neurons and inhibitory neurons; these 
two neuronal classes are distinguished by the effects the have on the post-
synaptic neurons they synapse with. 
Excitatory neurons are the more common of the two; these neurons either 
directly or indirectly transfer positive charge to downstream neurons, 
bringing them closer to generating an action potential. This is achieved 
through two methods; direct transmission of the action potential or through 
the release of neurotransmitters. In direct transmission, ion channels 
embedded within the pre- and post-synaptic sides of a synapse directly bridge 
the two neurons, allowing charged ions to flow between the two cells. When 
an action potential reaches a synapse, ion flow directly transfers the action 
potential across the synapse allowing it to continue propagating in the post-
synaptic neuron. Indirect excitation is performed through neurotransmitter 
release. When the action potential reaches a synapse, it causes 
neurotransmitter filled vesicles to bind to the cellular membrane at the 
synapse and release the neurotransmitter into the synaptic cleft. In the 
mammalian CNS, the main excitatory neurotransmitter is the molecule 
glutamate (Glu). The released neurotransmitters then bind to gated ion 
channels on the post-synaptic cell membrane, opening them and allowing 
positive ions to flow into the neuron. 
Inhibitory neurons function similarly to excitatory neurons, with the key 
difference being the neurotransmitters they release. Inhibitory neurons 
primarily use the neurotransmitter 𝛾–aminobutyric acid (GABA). When 
released into the synaptic cleft, GABA primarily acts on chlorine channels 
that allow negatively charged Cl-1 into the postsynaptic neuron. This 
hyperpolarizes the post-synaptic neuron below the resting potential, making 
it more difficult for it to generate an action potential. In the healthy brain, 
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inhibition is used to prevent excitation of unneeded neurons within or 
adjacent to a network, and to synchronize neuronal activity. It is also 
important to note that GABA has a complex effect on neurons, and that 
under certain circumstances it can also have a net excitatory effect on a 
neuron [10], [17], [18]. 
1.2.2.4     The Role of Glial Cells 
In addition to the neurons themselves, the CNS is composed of a diverse 
family of cells collectively known as glial cells. These cells are responsible for 
both protecting the neurons, and ensuring neurotransmission can occur 
efficiently through a variety of mechanisms. Most importantly related to this 
thesis, one type of glial cell known as the astrocyte works with neurons to 
maintain the chemical environment needed for effective neurotransmission. 
Astrocytes wrap around the synapses that connect neurons, and take up any 
neurotransmitters released into the synapse. Once inside the astrocyte, 
neurotransmitters can be broken down and their components transported 
back to the neuron, where the neurotransmitter can be resynthesized as 
needed. The most important example of this is the glutamate-glutamine-
GABA cycle, where glutamate that has been used for neurotransmission is 
taken up by astrocytes and converted into glutamine. Glutamine can then 
either transferred back to excitatory neurons to resynthesize glutamate, or 
the astrocyte can convert glutamine into GABA for distribution to inhibitory 
neurons [10], [19]. 
1.2.2.5     Neurotransmission and Epilepsy 
In epilepsy, the process of neurotransmission and action potential generation 
is altered. Epilepsy ultimately results from an imbalance of excitation and 
inhibition within a neuronal network. This imbalance can be caused by 
dysfunction at any point in the process of neurotransmission, including 
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under-expression, over-expression, or malformations of various ion channels 
that result in abnormal ion flow. These alterations create inhibitory neurons 
that require extra stimulation to fire and excitatory neurons that easily fire 
with minimal stimulation. Dysfunction of the astrocytes can also prevent 
glutamate from being cleared from the synaptic cleft, allowing glutamate to 
persistently allow positive charge into a neuron after the initial action 
potential has been generated. Dysfunction of both neurons and astrocytes can 
cause deregulation of the surrounding chemical environment, which can 
prevent normal ion flow from repolarizing a neuron after excitation, and can 
cause GABA to switch from having a net inhibitory to a net excitatory effect 
[17]–[22].  
 While the mechanisms can vary greatly, the net effect is much the same; the 
imbalance of excitation and inhibition creates a positive feedback loop in the 
effected areas of cortex. Some neurons will begin to fire in a continuous or 
hyper-synchronous manner, which rapidly propagates throughout the 
surrounding network. Without appropriate inhibition, positive feedback loops 
within the normal neural circuitry allow this abnormal firing to both 
reinforce itself and propagate throughout the brain, preventing normal brain 
function [11], [12], [23].  Under healthy conditions, neurons that fire together 
develop stronger connections to one another through a variety of mechanisms 
regulating protein expression within their synaptic connections. Seizures 
stimulate these same processes, creating long-term changes that predispose 
the affected neuronal circuitry to generate additional seizures in the future. 
If neurons continue to fire over a prolonged seizure, excess intracellular 
concentrations of ions such as Ca2+ create a neurotoxic environment, 
resulting in neuron damage and death as well as proliferation of glial cells 
such as astrocytes. This damage to cerebral tissue results in long-term 
cognitive deficits and visible lesions in epileptic patients [5]. 
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1.2.3     Epileptogenesis and Epilepsy Risk Factors 
Epileptogenesis, or the process by which seizure forming tissue regions 
develop and grow, is a complex topic that is still not fully understood. As 
stated in the ILAE definition of epilepsy, the term ‘epilepsy’ covers a wide 
range of diseases and disorders that cause seizures [1]. Generally speaking 
any insult to or malformation of the brain can lead to epileptogenesis, with 
the main causes being traumatic brain injury, cerebral tumours, viral or 
parasitic infections, malformations of the brain during development, and 
genetic mutations that alter the various cellular systems used to generate 
and regulate action potentials. The precise causes and mechanisms fuelling 
epilpetogenesis are highly variable between patients; understanding how and 
why these processes develop is an active area of research [23]. 
Also important to note is that epileptogenesis is an ongoing process. While 
the early stages of epileptogenesis are difficult to study in humans, because 
the process begins prior to a patient’s first seizure, it is known that the 
location and extent of seizure forming tissue can grow and evolve over time 
as seizures damage tissue and the brain responds to that damage. This 
ongoing change is important to consider from a clinical perspective, as 
patients with epilepsy can become more or less difficult to treat over time [1]. 
At present, epileptogenic processes cannot be reversed by existing epilepsy 
treatments. Evidence shows certain treatments can alter the development of 
epilepsy to reduce its severity in select circumstances, but there is no general 
anti-epileptogenic treatment that would be a true cure for epilepsy [23].  
1.2.4     Treatment 
When assessing epileptic patients, neurologists assess several risk factors 
that provide clues about the underlying pathology causing epileptogenesis, 
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which can be used to guide treatment. These questions include any history of 
head injury, whether the patient suffered from a provoked seizure (such as a 
febrile seizure in infancy), and any family history of epilepsy that would 
suggest a genetic component to the patient’s condition. 
The primary method for treating epilepsy is the use of anti-epileptic or anti-
seizure drugs (AEDs). These pharmacological treatments make use of a 
variety of treatment pathways; most stimulate the brain’s inhibitory 
pathways to counter the increase in neural excitability that causes seizures. 
AEDs are effective at controlling seizures for approximately 70% of patients 
diagnosed with epilepsy, with varied effectiveness based on the type of 
epilepsy syndrome [9], [24]. If a patient has tried two or more AED’s which 
have failed to adequately control their seizures, or if those drugs did control 
their seizures but with unacceptable side effects, then clinicians will diagnose 
that patient with a drug-resistant form of epilepsy [25].  
For patients with drug-resistant epilepsy, there are few treatment options 
available to them. Some forms of juvenile epilepsy can be controlled by the 
use of a ketogenic diet, however the efficacy of this diet in controlling adult 
epilepsy is still an area of active research. The predominant treatment for 
drug resistant patients is neurosurgery. A neurostimulation device is 
sometimes used, but the more common treatment is resective surgery to 
disconnect or remove seizure-forming regions from the rest of the brain [25].  
1.2.4.1     Electroencephalography in Epilepsy 
Electroencephalography (EEG) is a technique that uses electrodes to record 
electrical activity in the brain. In a typical scalp EEG measurement, a 
network of electrodes is placed at standardized positions around the head, 
using a conductive gel to improve electrical conductivity between the skin 
and the electrodes. As discussed above, neurons communicate using electrical 
 15 
currents; as neurons fire they create a change in voltage that is detected by 
an EEG system. By comparing the difference in voltage between different 
electrodes, brain activity can be localized to specific regions. Due to the low 
voltage of the current generated by neurons, combined with the interference 
created by the various layers of tissue and bone between the brain and the 
scalp electrodes, EEG requires hundreds of millions of neurons to fire 
simultaneously to generate detectable signal. Furthermore, the limited 
current makes it challenging for scalp EEG to detect electrical activity in 
deeper brain structures. EEG is very good at identifying changes in electrical 
activity over time, but only gives general information as to where that 
activity is occurring [10], [26]. 
EEG, when paired with video monitoring, is the gold standard for diagnosing 
a patient with epilepsy. During an epileptic seizure, neurons begin firing with 
an unnatural level of synchronicity; this results in rapid, high amplitude 
changes in the EEG signal from regions affected by the seizure. Meanwhile, 
most epileptic patient EEGs show what are known as interictal discharges; 
abnormalities in EEG signal that suggest that a group of neurons have begun 
to fire with the synchronicity found in a seizure, but without the development 
of a seizure or any effects on patient behaviour [1], [26]. 
As discussed in more detail below, EEG is a key tool in the planning of 
epilepsy surgery. In addition to traditional scalp EEG, epileptologists will 
often use invasive EEG techniques, requiring either subdural or depth 
electrodes. These invasive techniques work on the same principles as scalp 
EEG, however the electrodes are surgically inserted into the cranial cavity to 
increase sensitivity and remove the interference created by the skull and 
other intervening tissues. Subdural electrodes consist of a strip of electrodes 
inserted between the skull and brain across areas of interest, whereas depth 
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electrodes consist of a series of electrodes embedded in a needle-like rod, 
which is then inserted into the brain structures under examination [26]. 
1.2.4.2 Pre-Surgical Planning in Epilepsy 
The success of resective surgery is highly dependant on accurate localization 
of epileptic foci to ensure that all seizure forming tissue is removed while 
simultaneously avoiding damage to functionally normal tissue. This 
localization process is a multi-modal process utilizing a combination of 
seizure semiology, EEG recordings, neuropsychological examination, and 
magnetic resonance imaging (MRI). When additional diagnostic information 
is needed, fluorodeoxyglucose positron emission tomography (FDG-PET), and 
single-photon emission computed tomography (SPECT) are added to the 
armamentarium of tools used to localize epileptogenic focus. Good surgical 
outcomes are more likely for patients for whom all these techniques converge 
on single clear site of dysfunction. In patients with ambiguous localization, or 
seizures that emerge independently from different regions, surgery can still 
have positive effects. Unfortunately, in these cases it is less likely to 
completely stop their seizures because epileptic tissue that is part of the focus 
can be missed in the first resection, allowing it to continue generating 
seizures [25]–[28].  
Typical surgical planning relies most heavily on EEG (often paired with video 
recordings to capture seizure semiology simultaneously with electrographic 
recordings) and MRI. EEG confirms the diagnosis of epilepsy and provides 
general localization of abnormal neuronal activity, while MRI provides 
imaging data to identify the extent of the abnormal tissue and help identify 
the underlying disease [27]. However, 20-30% of the epileptic population, 
depending on the type of epilepsy, have normal appearing clinical MRI scans 
that do not display any identifiable indicators of tissue abnormality. In these 
cases, FDG-PET and SPECT may be used to help localize dysfunctional 
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tissue, however these techniques have their limitations. FDG-PET has high 
spatial resolution, but gives no information on the underlying cause of the 
seizures. In addition, the hypometabolic anomalies associated with epilepsy 
on FDG-PET imaging expend well beyond the seizure focus, limiting 
localization utility. Meanwhile, while SPECT scans can identify epileptic foci 
using cerebral blood flow measures, SPECT results have poorer resolution 
and reliability than FDG-PET [28].  
In an attempt to fill this gap in epilepsy treatment, we are evaluating the use 
of magnetic resonance spectroscopy in presurgical planning; it is known that 
the biochemical properties of the brain are altered in epileptic regions, and it 
is hoped that a spectroscopic biomarker could be used to identify the extent of 
epileptic tissue in MR-normal patients. 
1.3     Magnetic Resonance 
Nuclear magnetic resonance (NMR) is a phenomenon that arises from the 
magnetic properties of certain atomic nuclei. NMR phenomena can be 
described using either classical electromagnetism or quantum mechanics; 
while quantum mechanics gives a more complete explanation of NMR effects, 
for almost all cases the quantum scenario simplifies to the same results as 
the classical explanation. The following explanation of NMR effects will detail 
the classical approach to NMR, using the formulations detailed in [29]–[31]. 
In the mathematical notation, vector quantities will be denoted in bolded 
text. 
1.3.1     Classical Electromagnetism 
In general, a movement of electrical charge will generate a magnetic field. 
For any object that generates a magnetic field, we can describe the magnetic 
field produced by using that object’s magnetic moment 𝝁: 
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 𝝁 =  
𝑞
2𝑚
 𝑳 =  𝛾𝑳 (1.1)  
 where q is the electric charge of the object, m is that object’s mass, 𝑳 is the 
angular momentum of the object, and 𝛾 is a quantity known as the 
gyromagnetic ratio. If we were to place this magnetic object within a uniform 
magnetic field 𝑩𝟎, it would experience a torque 𝜏 according to Equation 1.2: 
 𝜏 =  |𝝁||𝑩𝟎|𝑠𝑖𝑛𝜃 (1.2)  
 where 𝜃 is the angle between 𝝁 and 𝑩𝟎. This torque would cause the cause 
the magnetic moment to precess around 𝑩𝟎 with an angular frequency 𝜔 
determined by Equation 1.3: 
 𝜔 =  𝛾𝐵0 (1.3)  
For an idealized magnetic moment in a vacuum, this precession would 
continue indefinitely. In a more realistic scenario, dissipative forces will act 
on the magnetic object, causing it to lose the kinetic energy associated with 
precession until the object reaches an equilibrium position where potential 
energy is minimized: 
 𝐸𝑀(𝜃) =  −𝝁 ∙  𝑩𝟎 =  −|𝝁||𝑩𝟎| 𝑐𝑜𝑠𝜃 (1.4)  
The torque produced by the externally applied magnetic field vanishes when 
the magnetic moment aligns parallel or anti-parallel to 𝑩𝟎 (𝜃 = 0° or 180°). If 
we now introduce a network of identical magnetic moments all within the 
same external 𝑩𝟎, the magnetic moments will align with 𝑩𝟎. By summing the 
magnetic field produced by these magnetic moments, we can describe a net 
magnetic field that is generated by the network.  
In principle, this effect is what is occurs in an NMR experiment; the nuclei of 
interest that are present within the sample generate their own magnetic 
moments, which are then aligned to an external magnetic field. The scale at 
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which NMR occurs complicates this picture. At the level of atomic nuclei, 
thermal energy becomes a major complicating factor that prevents the neat 
alignment of each nuclear magnetic moment along the applied magnetic field. 
Instead, the applied magnetic field gives the otherwise randomly distributed 
magnetic moments a slight bias to point along 𝑩𝟎 (which, by convention, is 
oriented along the z-axis). To explore this further we will examine the NMR 
behaviour of a hydrogen nucleus. 
1.3.2     NMR – A Proton’s Perspective 
As noted above, magnetic moments arise from a movement of charge. A 
hydrogen nucleus (1H) is composed of a single proton, and that proton has a 
quantum spin angular momentum. While the details of quantum spin are 
beyond the scope of the current explanation, it is worth nothing that the 
quantum nature of spin simplifies the current problem. Unlike a classical 
rotating object, where angular momentum can be gained or lost through 
interactions with the surrounding environment, quantum spin is an intrinsic 
property of the particles under discussion and thus is a constant quantity. 
Thus, all protons have the same constant angular momentum and by 
extension the same constant magnetic moment:  
 
𝜇 =  𝛾𝐿 =  
𝛾ℏ
2
 
(1.5)  
where ℏ is Planck’s constant. The macroscopic behaviour observed in NMR 
experiments is a result of the behaviour of a large number of nuclei. To 
translate these effects from an individual nucleus to a large collection of 
nuclei requires the use of Boltzmann statistics.  According to Boltzmann 
statistics, the probability that a proton will be oriented at an angle 𝜃 with an 
externally applied magnetic field 𝑃(𝜃) is: 
 20 
 
𝑃(𝜃) =
exp (−
𝐸𝑀(𝜃)
𝑘𝑇 )
∫ exp (−
𝐸𝑀(𝜃)
𝑘𝑇 ) 𝑠𝑖𝑛𝜃 𝑑𝜃
𝜋
0
 
(1.6)  
where 𝐸𝑀(𝜃) is the potential energy of a proton at angle 𝜃 with the z-axis (see 
Equation 1.4), T is the temperature of the system in Kelvin, and k is 
Boltzmann’s constant. From this, the average net magnetization along the z-
axis from a single proton 〈𝜇𝑧〉 is: 
 
〈𝜇𝑧〉 =  ∫ 𝑃(𝜃) ∗ 𝜇 𝑐𝑜𝑠𝜃 𝑠𝑖𝑛𝜃 𝑑𝜃
𝜋
0
≈  
𝛾2ℏ2𝐵0
4𝑘𝑇
 
(1.7)  
If we have a sample composed of N 1H nuclei, we can calculate the net 
magnetization for a sample (𝑀0) by summing the contribution from each 
proton: 
 
𝑀0 =  𝑁〈𝜇𝑧〉  ≈  
𝛾2ℏ2𝑁𝐵0
4𝑘𝑇
 
(1.8)  
where N is the total number of nuclei in our system. From this, we can easily 
identify the experimental factors that affect the strength of the NMR effect; 
the number of 1H nuclei in the sample, sample temperature (measured in 
Kelvin), the strength of our applied magnetic field, and the gyromagnetic 
ratio of the nucleus being examined.  
It is worth noting at this point that the behaviour derived above can be 
extended to other atomic nuclei beyond 1H. The mathematics involved are the 
same in principle, but are complicated by the presence of additional nucleons; 
as with the proton, the neutron also has quantum mechanical spin and 
generates its own dipole moment; these moments add to produce the 
magnetic moment of a more complex nucleus. Here the gyromagnetic ratio 
becomes an important factor; larger and more complex nuclei have a smaller 
charge to mass ratio. This results in a smaller gyromagnetic ratio, which in 
turn means a smaller 𝑀0 is generated for larger nuclei under constant 
experimental conditions. This fact, combined with the naturally high 
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abundance of 1H in biological systems has made hydrogen the primary 
nucleus of interest in medical applications of NMR. 
1.3.3     Excitation  
The utility of NMR comes from our ability to link the physical properties of 
the sample to the behaviour of sample magnetization. There is very little 
useful information that can be gleaned from simply measuring sample 
magnetization while is it statically aligned along the z-axis (often referred to 
in NMR as the longitudinal axis). However, if we can push sample 
magnetization away from equilibrium such that it has a component in the xy-
plane (also know as the transverse plane), the natural precession of 
magnetization around 𝐵0 can be manipulated to reveal a wide range of useful 
information. Transverse magnetization is typically generated by applying a 
second, time varying magnetic field 𝐵1(𝑡) which oscillates sinusiodally with 
the same frequency as the precessing nuclei in our sample (𝜔), known as the 
Larmor frequency: 
 𝐵1(𝑡) = |B1(𝑡)|sin 𝜔𝑡 (1.9)  
This has the effect of rotating the entire distribution of magnetic moments 
away from the z-axis by an angle determined by the duration and amplitude 
of the pulse used.  
In modern NMR techniques, pulsed 𝐵1(𝑡) fields, where the amplitude of 𝐵1(𝑡) 
is modulated over time, are almost universally used. The oscillatory 
frequency for this pulse as defined in Equation 1.9 falls into the radio 
frequency range for NMR experiments; as a result, 𝐵1(𝑡) is commonly 
referred to as a radiofrequency (RF) pulse. A given RF pulse will excite signal 
across a range of frequencies centered on the Larmor frequency. To take 
advantage of this, the amplitude modulation of 𝐵1(𝑡) in the time domain is 
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specifically tailored to give a desired frequency selection profile, while the 
duration of the pulse can be changed to give a desired frequency bandwidth. 
1.3.4     Signal Detection 
Detection of NMR signal relies on the principles of electromagnetic induction, 
which describes how a changing magnetic field generates electrical currents 
within a conductor: 
 
Φ𝐵 =   ∫ 𝑩(𝒓, 𝑡) ∙ 𝑑𝑨 
(1.10)  
 
𝜖 =  −
𝑑Φ𝐵
𝑑𝑡
 
(1.11)  
where 𝜖 is the voltage generated, A is the area of the conductor where voltage 
is being induced, and Φ𝐵 is the magnetic flux through this area. In a simple 
NMR experiment, signal detection is achieved by placing a simple loop of 
wire adjacent to our sample with its cross sectional area parallel to 𝑩𝟎. In 
this position, the precessing magnetization generates a sinusoidally varying 
voltage within the loop, which can then be measured as NMR signal. More 
complex NMR and MRI systems make use of more complicated conducting 
arrays that exploit this same principle, but are able to collect more detailed 
information over a region of interest.  
1.3.5     Relaxation 
Once magnetization has been pushed into the transverse plane, a variety of 
mechanisms will return it to equilibrium in a process known as relaxation. 
This process occurs exponentially, as described by Equations 1.12 and 1.13: 
 
𝑀𝑧(𝑡) =  𝑀0(1 − 𝑒
−
𝑡
𝑇1) 
(1.12)  
 
𝑀𝑋𝑌(𝑡) =  𝑀0𝑒
−
𝑡
𝑇2 
(1.13)  
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where 𝑇1 is the relaxation constant which dictates how fast equilibrium 
magnetization is restored along the longitudinal axis, 𝑇2 is the relaxation 
constant which dictates haw fast signal in the transverse plane disappears, 
and t is the time elapsed since excitation.  
Relaxation is heavily dictated by the microenvironment experienced by 
individual magnetic moments within a sample. Molecular motion and the 
precession of neighbouring magnetic moments cause small fluctuations in the 
magnetic field seen by a given magnetic moment. In 𝑇1 relaxation, these local 
fluctuations cause precessing nuclei to lose energy to the surrounding 
environment. This energy loss only occurs when the fluctuations occur at or 
near the Larmor frequency. It is worth highlighting that 𝑇1 relaxation is 
effected by 𝑩𝟎 field strength. Equation 1.3 shows that the Larmor frequency 
depends on 𝑩𝟎; as 𝑩𝟎 increases, higher frequency fluctuations are required to 
return magnetization to the z-axis. As the frequency of molecular motion 
within our sample is constant with magnetic field, this increase in 𝑩𝟎 
lengthens 𝑇1 relaxation by increasing the frequency separation between 
molecular motion and resonance frequency.  
𝑇2 relaxation is caused by similar mechanisms, but crucially in 𝑇2 relaxation 
energy is simply exchanged between moments within a sample and there is 
no net energy loss to the surrounding environment. When signal is excited in 
an NMR experiment, transverse relaxation is created by the coherent 
precession of nuclei around 𝑩𝟎. Fluctuations in the field seen by each nucleus 
causes variations in precession frequency, leading to a loss of coherence and 
hence a loss in transverse magnetization over time. This loss of coherence 
largely results from low frequency magnetic fluctuations; these effects are 
amplified as we move to very high field strengths, leading to shorter 𝑇2 
relaxation times. 
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Up to now we have assumed that the applied 𝐵0 is an ideal, completely 
uniform field. In reality this field is generated over a finite region and hence 
is heterogeneous to some degree across a sample. In addition, the sample has 
an effect on 𝐵0; different materials have different magnetic properties, and 
when there is a transition between different materials within a magnetic 
field (such as the transition between a sample and the surrounding air) 
fluctuations in 𝐵0 occur. Modern MRI systems come equipped with hardware 
known as shimming coils that are used correct for gross inhomogeneities in 
𝐵0; however, small variations are omnipresent in any real NMR experiment. 
These non-idealities are important from a relaxation standpoint as they can 
dramatically speed up transverse relaxation. For a given magnetic moment, 
the resonance frequency depends on the total local magnetic field 
encountered by that moment; generalizing Equation 1.3, we find: 
 𝜔 =  𝛾𝐵 =  𝛾(𝐵0 +  ∆𝐵) (1.14)  
where ∆𝐵 represents any variation in 𝐵0 due to magnetic inhomogeneities, 
applied 𝐵1 fields, or applied magnetic gradients (discussed below).  
These shifts in the resonance frequency across the sample due to 𝐵0 
inhomogeneities causes our magnetization to dephase much more rapidly 
than theoretical 𝑇2 decay. However, because these inhomogeneities are 
constant in time and space their effect can be reversed using by RF pulses to 
invert phase. For this reason, the simple observed transverse relaxation in a 
given experiment is referred to as 𝑇2
∗ decay, and we reserve the term 𝑇2 
relaxation for the irreversible decay previously described (Figure 1.5).  
1.3.6     Gradients 
The most powerful tool available to link the physical properties of a sample to 
its magnetization is the magnetic gradient. By applying a linearly varying 
magnetic gradient across a sample, we can linearly vary the resonance   
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Figure 1.5 - Simple Pulse 
Sequences Illustrating 
Relaxation Effects: (A) shows 
a Free Induction Decay where 
signal decays exponentially at 
the rate T2* (dotted line). (B) 
shows a Spin Echo where the 
echo rises and falls 
exponentially according to T2*. 
(C) shows a Carr-Purcell-
Meiboom-Gill (CPMG) echo 
train, which uses a series of 180 
degree RF pulses to refocus an 
echo multiple times. Here the 
maximum amplitude of each 
echo decreases exponentially at 
the rate T2. 
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frequency of nuclei across our sample in a highly controlled manner (see 
Equation 1.14). This creates a spatial dependence between signal phase and 
position that has two main uses.  
When applied in conjunction with an RF pulse, an applied magnetic gradient 
can excite signal from a slab or slice of the sample, and is known as a slice 
select gradient. As mentioned above, RF pulses excite signal from any 
precessing moments that fall within a certain frequency range around the 
Larmor frequency. By varying the strength of a magnetic gradient, signal 
from specific slices of the sample can be excited and acquired, allowing for 
localized NMR measurements within a large or heterogeneous sample.  
Gradients are also fundamental for producing images. The relationship 
created between resonance frequency and position created by magnetic 
gradients can be exploited to produce dependence between the position of a 
magnetic moment within the MR system and its phase. Stated simply, the 
inverse Fourier transform of an NMR signal acquired in the presence of a 
magnetic field gradient returns the frequency distribution of the signal 
induced by the gradient, which can be used to recover the spatial distribution 
of magnetization, producing an image of the sample. 
1.3.7     Magnetic Resonance Spectroscopy 
Magnetic resonance spectroscopy (MRS) is a technique that allows for the 
identification and quantification of different chemical species within a 
sample.  
1.3.7.1     Chemical Shift 
Prior to this discussion, we have been tacitly assuming that our hypothetical 
sample was composed exclusively of 1H nuclei. In reality, this picture is 
complicated by the presence of chemical structure within a sample and the 
electrons that form these structures. As with protons and neutrons, electrons 
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generate their own magnetic dipole that causes a slight local variation in 𝐵0. 
This causes a shift in the resonance frequency between 1H nuclei attached to 
different molecules, and between chemically non-equivalent 1H nuclei within 
the same molecule. These variations from the Larmor frequency occur by a 
fixed percentage (usually measured in parts-per-million, ppm) and are 
heavily dependent on the chemical structure of the molecule. Magnetic 
resonance spectroscopy exploits this behaviour to identify different chemical 
species. Using the Fourier transform, a time-domain signal collected from an 
NMR system is decomposed into its frequency components, allowing us to 
visualize the resonance frequencies present within a sample. Using either 
computer simulations or phantom measurements of a single molecule of 
interest in isolation, the characteristic pattern of frequency shifts, peak 
amplitudes, and phases can be modeled for that molecule of interest. This 
information is then used to identify that molecule from a more complicated 
spectrum composed of many molecules (Figure 1.6).  
The signal amplitude in NMR is proportional to the number of nuclei 
generating that signal. Following a Fourier transform, this relationship 
results in the number of nuclei involved instead being proportional to the 
area under the corresponding spectral peak. This allows the concentration of 
chemicals to be measured quantitatively by comparing the area under the 
spectral peaks of different molecules to a reference signal with known 
concentration. 
1.3.7.2     J-coupling 
While chemical shift is primarily responsible for MRS phenomena, these 
spectra are further shaped by the phenomenon of J-coupling. To explain J-
coupling we must briefly invoke quantum mechanics. In quantum mechanics 
there is a principle known as Pauli’s exclusion principle. This rule simply 
states that particles with half integer spin cannot occupy the same quantum 
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state within the same system simultaneously (i.e. different particles within a 
system must be distinct). Protons, neutrons, and electrons all have half  
integer spin and hence all follow this rule. However, for our purposes this 
principle is most important for the electron. 
When bound to an atom or molecule, electrons are confined by quantum 
mechanics to a discrete set of orbitals surrounding their parent nuclei; each 
orbital can contain up to two electrons. Electrons within the same orbital by 
definition share many quantum properties, leaving quantum spin (m) as the 
only variable that can be used to distinguish between them. As a result, for  
pairs of electrons within the same orbital, one electron must be in a spin 
down state (𝑚 =  ½), and the other must be in a spin up state (𝑚 =  − ½). 
When applied to the electrons that bind a molecule together, the exclusion 
principle provides a mechanism for nuclei to affect the chemical shift of other 
nuclei they are chemically bonded to. The polarization of one nucleus along 
the z-axis in a molecule will affect the polarization of its accompanying 
electrons. This restricts the polarization of electrons from other nuclei that 
share orbitals connecting the first nucleus to a second, thus subtly affecting 
the chemical shift of this second nucleus. This effect is not simply restricted 
to adjacent nuclei, but can alter the signal from chemically distinct nuclei up 
to 3 chemical bonds away from one another.  
In an MR spectrum, this effect causes spectral peaks to be split into multiple 
daughter peaks (Figure 1.7). This information can be useful because it 
contains information about the structure of the molecule. However, 
depending on the strength of the coupling, this can lead to a substantial 
decrease in the signal to noise ratio (SNR) of a spectrum, and cause 
significant overlap between signals from different molecules, increasing 
measurement difficulty.  
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Figure 1.6 – Fit 7T semi-LASER Spectrum Collected from the Hippocampus:  
Spectrum collected from a human hippocampus (blue), overlaid with fit spectrum (orange) 
and residual noise (green). Below, the fit spectrum is broken down into the contributions 
from individual metabolites. Data was acquired using a semi-LASER sequence (See section 
1.3.7.6) 
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Figure 1.7 - Example J-coupling Multiplets: Example multiplets from NMR experiments; if J-coupling were not a factor, all these 
multiplets would stack on top of one another to create a single, high amplitude peak. 
Multiplet image by ChemistHans at English Wikipedia [Public domain], via Wikimedia Commons 
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1.3.7.3     Spectroscopic Techniques 
To collect a spectrum one simply has to excite nuclei within the sample, then 
record and Fourier transform the resulting signal waveform. However, 
particularly for medical applications, spatial localization of spectroscopic 
signal is necessary to identify metabolic change in abnormal, diseased, or 
damaged tissue. As a result, a variety of techniques have been developed to 
encode spatial information. The simplest forms of localized spectroscopic 
techniques are known as single voxel techniques; these techniques collect 
bulk signal from a specific region of interest. In all single voxel techniques, 
three slice selective gradients applied across the x-, y-, and z-axes are used to 
selectively excite signal from the region of interest. For a more detailed view 
of a region of interest, magnetic resonance spectroscopic imaging (MRSI) can 
be used. This technique involves collecting spectra from voxels arranged in a 
grid pattern across a region of interest to generate maps of different 
metabolite levels across that region.  
The key limitation on the use of spectroscopic techniques in medical practice 
is the low concentration of most metabolites in vivo. As shown in Equation 
1.8, sample magnetization (and hence sample signal) is proportional to the 
number of relevant nuclei being excited. While water is highly concentrated 
in tissue (with an average concentration of ~50 M in the human brain), many 
of the metabolites of interest in in vivo NMR have relatively low 
concentrations on the order of mM.  This has two effects; first, to accurately 
quantify metabolite signal, water suppression techniques must be employed 
to prevent water signal from completely overwhelming the rest of a spectrum. 
Second, the low metabolite signal results in a low SNR for these spectral 
peaks. To accurately quantify metabolite levels, signal averaging is often 
necessary to boost SNR, which results in long scan times that are not ideal in 
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a clinical environment. This is particularly true for MRSI techniques that 
require the collection of multiple spectra across a sample. 
1.3.7.4     Data Analysis Methods and Techniques 
In MRS, the exact data analysis steps taken to convert from an MRS 
spectrum to a measure of concentration varies between different research 
groups. Discussed here will be the analysis techniques used for the research 
presented in Chapter 2. 
Prior to analysis, spectral data typically undergo some pre-processing to 
improve spectral quality. Time and spatially varying field inhomogeneities 
may distort the shape of the peaks within a spectrum, making the 
quantification process more difficult. To reduce this effect, various lineshape 
corrections are possible. In this study presented in Chapter 2, we utilized a 
combined QUALITY deconvolution [32] and eddy current correction [33] 
(QUECC) technique to ensure spectral peaks all had a Lorentzian lineshape 
[34]. 
Metabolite concentration is calculated from an MRS spectrum based on the 
relationship between the number of nuclei generating a signal and the signal 
amplitude. By measuring the amplitude associated with each metabolite in 
the time domain, concentration can be calculated. This amplitude is 
measured by fitting a simulated metabolite prior knowledge lineshapes, 
generated using the PyGamma pulse sequence simulation tools [35], to the 
acquired data. A Levenberg-Marquard minimization routine is used to 
minimize the difference between the data and the prior knowledge 
lineshapes. The model is constrained in how it can fit the data to ensure 
errors do not occur; for example, if the fit for a specific spectral peak falls 
outside of the given constraints, then that peak’s time domain amplitude is 
fixed to zero and fitting is re-started. Once the data is accurately fit, the 
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signal amplitudes of each metabolite determined from the fit are used to 
calculate concentrations [36], [37]. 
Concentration is commonly calculated in the brain either as absolute values 
in mM using water as an internal reference signal, or as a ratio to the 
molecule creatine (Cr). Ratios to creatine were calculated by summing the 
peak amplitudes that contribute to a particular metabolite spectrum, then 
dividing by the total amplitude of Cr (Equation 1.15): 
 
𝑋 𝐶𝑟⁄ =  
Σ𝑆𝐴𝑚𝑝,𝑋
Σ𝑆𝐴𝑚𝑝,𝐶𝑟
 
(1.15)  
where 𝑋 𝐶𝑟⁄  is the concentration of the metabolite of interest X as a ratio to 
Cr, and Σ𝑆𝐴𝑚𝑝,𝑋 and Σ𝑆𝐴𝑚𝑝,𝐶𝑟 are the total amplitude of all peaks that form the 
spectral line shape of the metabolite of interest and Cr. 
Absolute concentration calculations, which give metabolite concentration 
within the combined grey/white matter tissue fraction of the voxel, were 
evaluated using Equation 1.16: 
 
[𝑋]𝑇𝑖𝑠𝑠𝑢𝑒 =  
Σ𝑆𝐴𝑚𝑝,𝑋
Σ𝑆𝐴𝑚𝑝,𝐻2𝑂
 
𝑛𝜌,𝐻2𝑂
𝑛𝜌,𝑋
𝑅𝐻2𝑂
𝑅𝑋
∗ [𝐻2𝑂]𝑉𝑜𝑥𝑒𝑙 ∗ (𝐺𝑀 + 𝑊𝑀) 
(1.16)  
   
 
𝑅𝑋 =  𝐺𝑀 (1 − 𝑒
−
𝑇𝑅
𝑇1,𝐺𝑀) (𝑒
−
𝑇𝐸
𝑇2,𝐺𝑀)
+  𝑊𝑀 (1 − 𝑒
−
𝑇𝑅
𝑇1,𝑊𝑀) (𝑒
−
𝑇𝐸
𝑇2,𝑊𝑀) 
(1.17)  
Where [𝑋]𝑇𝑖𝑠𝑠𝑢𝑒 is the concentration of the metabolite of interest within the 
tissue fraction of the MRS voxel, 𝑛𝜌,𝐻2𝑂 and 𝑛𝜌,𝑋 are the number of protons 
producing spectral signal for both water and the metabolite of interest, 𝑅𝑋 
and 𝑅𝐻2𝑂 are the combined 𝑇1 and 𝑇2 relaxation for both the metabolite of 
interest and water in grey and white matter (See Equation 1.17), [𝐻2𝑂]𝑉𝑜𝑥𝑒𝑙 is 
the average concentration of water within the voxel, and (GM+WM) is the 
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voxel tissue fraction for grey and white matter [38]. This last correction was 
included to ensure that the calculated metabolite concentration was the 
average concentration within the tissue component of the voxel, and not from 
the voxel as a whole. For this calculation, voxel tissue volume fractions were 
evaluated using the Oxford Centre for Functional MRI of the Brain (FMRIB) 
software library (FSL) [39]; images were brain extracted and segmented 
using FSL's Brain Extraction Tool (BET) [40] and FMRIB's Automated 
Segmentation Tool (FAST) [41]. Literature reported relaxation and water 
concentration values were used for this calculation [42]–[45].  
1.3.7.5     Effects of Field Strength in Spectroscopy 
As previously mentioned, the low concentration of metabolites in vivo results 
in a low SNR in MRS measurements, which in turn decrease the clinical 
utility of MRS by requiring long scan times. Looking back to Equation 1.8, 
the only factor that can be manipulated to increase SNR for an in vivo 
measurement is 𝐵0. In addition, as mentioned in the discussion of chemical 
shift, the shift between different spectral peaks is a fractional change away 
from the Larmor frequency. By increasing 𝐵0, the frequency separation 
between different spectral peaks increases (spectral dispersion), making it 
easier to separate overlapping peaks, allowing for the independent 
measurement of metabolites that are heavily overlapped at lower field 
strengths. For these two reasons, MRS can greatly benefit from an increase 
in 𝐵0 field strength, leading to a push to perform MRS on the strongest 
possible magnets. 
However, while an increase in 𝐵0 had considerable benefits, it also increases 
magnetic field inhomogeneities in biological tissues. MRS relies on the 
resolution of frequency shifts to identify different molecules. However, 
frequency shifts can also be caused by variations in 𝐵0 within a region of 
study. With 𝐵0 variation, spectral peaks become wider and the SNR of a 
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collected spectrum decreases, potentially countering the benefits of higher 
field strength. Importantly, magnetic susceptibility artefacts increase with 
𝐵0. At ultra-high field strengths (≥ 7T), these non-uniformities must be 
corrected using a combination shimming hardware and inhomogeneity 
insensitive MRS pulse sequences to preserve the benefits of increased field 
strength. In addition, the increase in Larmor frequency requires higher 
energy B1 fields, which are in turn harder to generate uniformly across a 
sample, and can lead to power deposition restrictions. 
An additional source of error in MRS localization that increases with field 
strength is the chemical shift displacement error (CSDE). Spatial localization 
is achieved for MRS primarily through frequency selective excitation; a 
gradient is applied across a sample, then an RF pulse excites signal from a 
specific range of frequencies that correspond to the region of interest. 
However, in MRS the excited signal contains substantial contributions from 
metabolite peaks that are not oscillating at the Larmor frequency prior to 
gradient application. This means that the signal from each spectral peak 
comes from a slightly different voxel, with a displacement given by Equation 
1.18:  
 
Δ𝑥 =  
Δ𝜔
Δ𝜔𝑚𝑎𝑥
𝑉𝑥 
(1.18)  
where Δ𝑥 is the change in position for the centre of the voxel along the x-axis, 
Δ𝜔 is the chemical shift between two spectral peaks, Δ𝜔𝑚𝑎𝑥 is the bandwidth 
of the slice selective RF pulse, and 𝑉𝑥 is the voxel length along the x-axis. To 
minimize CSDE either high powered gradients, or high bandwidth RF pulses 
must be used during slice selection [30]. 
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1.3.7.6     Semi-LASER 
Localization by adiabatic selective refocusing (LASER) [46] is a spectroscopy 
localization sequence designed to acquire high quality MRS spectra from well 
defined voxels at ultra-high field strengths. A slight variant of this sequence 
called semi-LASER uses a simple, slice selective sinc shaped 90° RF pulse to 
excite signal, followed by two pairs of slice selective adiabatic full passage 
(AFP) pulses to localize signal to a single voxel of user specified dimensions 
(Figure 1.8). The sequence produces a spin echo; the second half of the echo is 
acquired and Fourier transformed to produce the MRS spectrum. 
Adiabatic pulses are a class of RF pulse that are both modulated in 
amplitude and frequency over the duration of the pulse. Theses pulses are 
designed to be less sensitive to 𝐵1 inhomogeneities than conventional pulses, 
and therefore particularly useful for high field applications where 𝐵1 may 
vary across a sample. In addition, adiabatic pulses can be designed to have  
large excitation bandwidths with arbitrarily long pulse durations. This has 
several advantages; for example, increasing pulse length allows for a 
decrease in pulse amplitude, which in turn reduces power deposition. 
Furthermore, high bandwidth pulses reduce chemical shift artefacts [30], 
[47], [48].  
There are also drawbacks associated with adiabatic pulses; for example, they 
take a long time to play out, resulting in long echo times that reduce SNR. 
Also, when used for slice selection, proper refocusing can only be achieved by 
using paired adiabatic pulses. This increases the total number of pulses and 
increases overall power deposition. The semi-LASER sequence is designed as 
a happy middle ground between more conventional single voxel techniques 
and LASER. In semi-LASER, localization is achieved using two slice selective 
AFP pulse pairs and a slice selective normal RF pulse at the beginning of the   
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Figure 1.8 - The semi-LASER Pulse Sequence: In this sequence, initial excitation is 
performed with a 90° sinc shaped slice select pulse. This is followed by two pairs of slice 
select adiabatic full passage pulses, which localize signal to a voxel within the sample while 
refocusing signal into a spin echo. The decay of this echo is then acquired and Fourier 
transformed to give an MRS spectrum 
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sequence, creating a balance between reduced echo time and power 
transmission [30], [47], [48]. 
1.4     Spectroscopy in Temporal Lobe Epilepsy 
MRS was first applied to the study of human epilepsy in the late 1980’s, with 
TLE being one of the first epilepsies examined [49]. In the decades since, 
dozens of research groups have examined TLE with MRS, the results of 
which are summarized below based on the metabolite of interest. 
1.4.1     Creatine 
Biologically, Cr acts as a buffer for cellular energy metabolism. Cr exists in 
two main forms in the human body; molecular creatine, and phosphocreatine 
(PCr). The enzyme creatine kinase can rapidly convert between these two 
molecules via the following reaction: 
𝐶𝑟 + 𝐴𝑇𝑃 ↔ 𝑃𝐶𝑟 + 𝐴𝐷𝑃 + 𝐻+ 
 turning adenosine triphosphate (ATP) into adenosine diphosphate (ADP) or 
vice versa in the process. ATP is the primary energy-carrying molecule in 
cellular processes; by storing high-energy phosphorus bonds in PCr, the cell 
creates an energy reservoir that can be used to rapidly replenish ATP levels 
in response to increased energy consumption. Furthermore, PCr is able to 
diffuse much faster throughout a cell than ATP, allowing for more efficient 
energy transport. In in vivo MRS studies, the signal from both forms of Cr 
overlap significantly with one another in the spectrum. As a result, Cr 
concentration is commonly measured as the total concentration of these two 
molecules [30], [50]. 
Creatine is particularly noteworthy in MRS studies of the brain in general 
because its concentration in vivo has been shown to be invariant with age 
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and invariant between healthy and diseased tissue in some diseases. This 
suggests that Cr is a good candidate as a reference signal with which to 
quantify other metabolites. As a result, many MRS studies report metabolite 
concentration as a ratio of the metabolite of interest to Cr (denoted as X/Cr). 
However, more recent work has shown that Cr is not constant between 
healthy and diseased tissue under a variety of conditions, making its use as a 
reference signal a potential source of error [30], [50]. Some argue that the 
potential variance in concentration undermines the accuracy of MRS 
measurements [50],  whereas others have commented that normalization to 
creatine still gives a useful measurement, as it potentially normalizes for the 
amount of biomass within a measured region [51]. 
In epilepsy, due to its common use as a reference signal, few studies report on 
the behaviour of Cr directly. In one study [9], Cr levels (measured as an 
absolute quantity using an internal water reference, hereafter denoted by 
enclosing metabolite shorthand within [square brackets]) were found to 
increase ipsilateral to seizure focus in patients with drug-resistant mesial 
temporal sclerosis. Meanwhile other studies did not observe changes in [Cr] 
in TLE patients with hippocampal sclerosis or in MRI-negative TLE patients 
[52], [53]. In another study [54], high resolution scans of resected epileptic 
tissue found that elevated [Cr] levels were associated with elevated seizure 
frequency, but were not different between samples with hippocampal 
sclerosis compared to samples with no visible lesion. 
1.4.2     N-Acetylaspartate 
N-Acetylaspartate (NAA) is one of the most highly concentrated metabolites 
within the brain; this in combination with its very prominent methyl singlet 
peak at 2.01 ppm makes it the easiest metabolite to measure in an in vivo 
spectrum. It is exclusively synthesized in neuronal mitochondria, making it a 
biomarker for neuronal health and density. NAA levels have been found to 
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decrease across a wide range of neurological disorders, and have been found 
to recover in some diseases in response to treatment [30], [50]. 
In TLE, decreased NAA levels ipsilateral to seizure focus are the most 
commonly reported metabolic changes, both when measured as the ratio 
NAA/Cr [55], [56] or NAA/(Cr+ Cho) [57]–[60], and as an absolute quantity 
[9], [52]. Studies have also found that NAA change is not limited to the 
epileptic focus; decreases in NAA have been reported outside of visible lesions 
ipsilateral to seizure focus [56], contralateral to seizure focus [55], and 
various regions of the frontal lobe [61], [62]. Using an MRSI technique, one 
study [63] showed that when the area of greatest NAA/Cr abnormality was 
resected, patients had better clinical outcomes. In MRI-normal TLE patients, 
changes in NAA appear to be less distinct. Some report the same NAA 
decrease as that seen in lesional TLE [64], while others report no difference 
between MRI-normal patients and healthy controls [52]. NAA levels may also 
be affected by seizure activity, as one study has found decreases in NAA/Cr, 
NAA/Cho, and NAA/(Cr+ Cho) when comparing patients immediately post 
seizure to their inter-ictal baseline [65]. 
1.4.3     Choline 
The choline (Cho) signal in NMR is the product of signal from a variety of 
choline containing molecules, namely free choline, phosphocholine, and 
glycerophosphocholine. These 3 molecules are all involved in the process of 
phospholipid synthesis and degeneration, and as a result changes in Cho in 
MRS are largely associated with membrane turnover. It is also important to 
note that Cho is readily transported across the blood brain barrier, as the 
brain does not synthesize enough to meet its needs. As a result, Cho levels in 
the brain can be affected by diet. Cho is the second most prominent peak from 
human brain spectra, because it contains 9 chemically equivalent protons 
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that do not experience substantial chemical shift effects between different 
Cho containing metabolites [30], [50]. 
In TLE, Cho is commonly included into the combined measure NAA/(Cho+Cr) 
or NAA/Cho, both of which have been shown to decrease ipsilateral to seizure 
focus [56], [57], [60], [62], [65]. In cases Cho is reported, it has been found to 
increase ipsilateral to seizure focus [9] or has shown no significant change 
[66]. In resected tissue, [Cho] was found to be lower in lesional TLE tissue 
compared to MRI-normal tissue [54]. 
1.4.4     Glutamate and Glutamine   
Glutamate (Glu) is the highest concentration amino acid in the central 
nervous system. However, unlike NAA or Cho none of the 5 protons on the 
Glu molecule are chemically equivalent. As a result, the Glu spectrum is split 
into a large number of low amplitude peaks. Furthermore glutamine (Gln), 
the precursor molecule for Glu, is structurally very similar to glutamate; this 
results in a high level of overlap between the spectra for these two molecules 
making them very hard to resolve independently at clinical field strengths. 
As a result, for in vivo studies they are almost always reported as a combined 
concentration (Glx). 
Biologically, glutamate is important because it is the primary excitatory 
neurotransmitter in the CNS. Importantly for epilepsy, Glu can also be 
neurotoxic. One of the receptors Glu activates allows positively charged Ca2+ 
ions into a neuron, which in sufficient quantities can cause cell death. 
Meanwhile, glutamine is a molecule that is synthesized from Glu in 
astrocytes. After a neuron releases Glu during neurotransmission, that Glu is 
taken out of the synaptic cleft by astrocytes. It is then converted from Glu to 
Gln so it can be safely transferred back to the neuron for re-synthesis of Glu 
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in what is known as the Glu-Gln cycle. In addition, Gln is used to synthesize 
the primary inhibitory neurotransmitter, GABA [30], [50]. 
In epilepsy, dysfunction of the Glu-Gln cycle is considered one of the potential 
causes of seizures, making Glx studies a key area of interest [8]. In TLE, the 
region of the brain involved further complicates evaluation of Glx. 
Specifically, the proximity of the temporal lobe to the base of the skull and 
sinuses results in increased 𝐵0 heterogeneity. This decreases the SNR of the 
spectrum and makes it challenging to separate Glx signal from noise at 
clinical field strengths. Of the studies that do report Glx levels, two did not 
find significant changes[66], [55], one found Glx/Cr decreased ipsilateral to 
seizure focus compared to controls and contralateral tissue [58], one found a 
significant increase in [Glu] and [Gln] in lesional TLE tissue compared to MR 
normal tissue [54], and one found that Glu increased in the frontal lobe of 
TLE patients [52]. 
1.4.5     Myo-Inosotol 
Myo-inositol (Myo) is the most prevalent form of inositol in the human body. 
Within the CNS, Myo is understood to take on several roles; it is part of the 
lipid component of biological membranes, it is an osmolyte used to maintain 
cell volume, and it both acts as and is used to synthesize secondary 
messenger molecules for intra-cellular communication. As with Cho, Myo is 
transported across the blood brain barrier and is primarily sourced both from 
synthesis elsewhere in the body and from dietary supplementation. In MRS, 
Myo has been proposed as a biomarker for glial cell activity. However, Myo 
has been shown to be taken up by neurons as well as glial cells, leading to 
questions about its specificity [30], [50]. 
In the study of TLE, levels of Myo/Cr have been reported to decrease 
ipsilateral to seizure focus in MRI-normal TLE patients [58], to increase 
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ipsilateral to seizure focus in patients with hippocampal sclerosis [52], and to 
decrease in frontal lobe in TLE patients [52], [61]. 
1.5     Thesis Outline 
To address our research question outlined in Section 1.1, we performed an 
MRS study of non-lesional TLE patients to identify metabolic abnormalities 
associated with this patient group. This study and its results are detailed in 
Chapter 2. The final chapter contains a brief overview of our results thus far, 
and the future direction in which this work could be taken. 
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2.1 Introduction 
Temporal Lobe Epilepsy (TLE) is one of the most common forms of focal 
epilepsy. Approximately 25-30% of patients with TLE have inadequate 
control over their seizures with drug treatments and are ultimately 
diagnosed with medically refractory epilepsy (MRE). Such patients are 
considered candidates for more invasive treatments such as surgical resection 
of the affected tissue. While resective surgery has a reasonably high success 
rate in this cohort, the effectiveness of surgery is diminished in patients 
without an identifiable structural abnormality on clinical magnetic resonance 
imaging (MRI) scans to guide the resection [1], [2]. 
These localization issues are not unique to TLE. One potential technique to 
help identify epileptic tissue in the MRI-normal population is the use of 
magnetic resonance spectroscopy (MRS). MRS techniques can discriminate 
different molecular species present within a tissue of interest using the 
unique spectral lineshape of each molecule determined by its chemical 
structure, and measure the concentration of these molecules. Unfortunately, 
the application of MRS in TLE is hampered by the proximity of many key 
structures of the temporal lobe, such as the hippocampus, to structures in the 
head with different magnetic susceptibility to that of the tissue.  Specifically, 
the base of the skull and the sinuses distort the magnetic field produced by 
the MR system, greatly reducing the signal to noise and overall quality of the 
resultant spectrum [3]. Most studies which examine metabolites with low 
MRS signal amplitudes within the temporal lobe have been forced to use 
either large voxel volumes, leading to ambiguity in the results due to the 
inclusion of multiple separate brain structures within the same voxel [4], [5], 
or they have restricted the metabolites under examination to those that can 
be accurately quantified in spite of poor spectral quality: N-acetylaspartate 
(NAA), total creatine (Cr), and total choline (Cho) [6]–[11]. 
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Several studies have previously examined non-lesional TLE. Decreases in 
NAA, NAA/Cr, and NAA/(Cr+ Cho) [7], [12]–[15] within the temporal lobe 
ipsilateral to seizure origin have been most consistently reported, although 
one study also showed no significant metabolite changes [4]. In addition, 
some metabolite changes have been found outside the temporal lobe in non-
lesional patients using both single voxel MRS and MRS imaging techniques. 
These studies have shown ipsilateral and extra-temporal decreases in 
NAA/(Cr+ Cho) [12], [13], [NAA] [16], and myo-inositol [4], [16], in addition to 
variable glutamate behaviour [4], [13]. Resected MRI-normal tissue has also 
been studied using high resolution magic angle spinning, revealing decreases 
in glutamate and glutamine and increases in NAA and Cho when comparing 
non-lesional tissue samples with samples containing hippocampal sclerosis 
[17]. 
The use of ultra high field human MRI scanners (≥7T) can improve MRS 
measurements in hard to measure regions of interest such as the 
hippocampus. The increased main magnetic field strength increases the 
signal to noise ratio (SNR) of the acquired spectra, while simultaneously 
increasing spectral dispersion, thereby reducing signal overlap and allowing 
metabolite signals to be resolved separately. In addition, higher power shim 
coil amplifiers can better correct field inhomogeneities, thereby improving 
magnetic field homogeneity within the tissue and consequently spectral 
quality [18]. The goal of the current study was to examine MRS changes in 
the hippocampus in TLE patients at 7T to confirm decreases in NAA and 
increases in Cho concentrations demonstrated by previous studies, while also 
examining previously hard to measure metabolites such as glutamate, 
glutamine, and Myo-Inositol.  
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2.2 Methods 
2.2.1 Patient Recruitment 
Patients between the ages of 18 and 90 were recruited through the Epilepsy 
Program at the London Health Sciences Centre. All participants provided 
informed consent for this study, which was approved by the Western 
University Health Sciences Research Ethics Board. All patients had been 
diagnosed with MRI-negative TLE during routine clinical treatment. Prior to 
recruitment, all patients underwent scalp and/or intracranial 
electroencephalography (EEG) and a 1.5T MRI scan as part of standard 
clinical care. Patients were excluded if they were unable to tolerate the 7T 
MRI scan protocol, if any vascular malformations or tumours were detected 
on their clinical MRI, or if they suffered from any other significant medical or 
psychiatric conditions. Age, sex, and handedness matched participants were 
also recruited to serve as a control group. 
In total, 24 patients were recruited, along with 24 healthy controls. Of these, 
useable data from at least one hippocampus were acquired from 19 patients 
(14 male, 6 female, average age 31.8± 11.6 years) and 20 healthy controls (14 
male, 7 female, average age 32.4± 8.6 years).  MRS data was not collected 
from the excluded participants either because of hardware issues or because 
patients could not tolerate the scan due to claustrophobia. Demographic 
information for all included patients is provided in Table 2.1, including side 
of seizure localization and duration of epilepsy. Acquired spectra were 
excluded from analysis if they had a signal-to-noise ratio <10 (N=3) and/or if 
the linewidth was greater than 24 Hz (N=2). Full datasets including spectra 
from both left and right hippocampi were obtained from 15 patients, while 
only a single useable spectrum was obtained from the remaining four 
patients. Full datasets were collected from 16 controls, with four controls only 
providing a single spectrum.  
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Table 2.1 – Patient Demographics and MRS Asymmetry Results – Clinical data and MRS results for all patients included in analysis; 
starred entries in the rightmost column indicate incorrect MRS lateralization. Directionality of metabolite change is based on whether 
concentration is increased () or decreased () in the left hippocampus relative to the right.
Subject ID 
Clinical Seizure 
Lateralization 
Duration of 
Epilepsy (Years) 
Seizure Frequency 
at Time of Scan 
Observed Asymmetry in 
Concentration Ratios  
(Left Hippocampus) 
Observed Asymmetry in 
Absolute Concentration 
(Left Hippocampus) 
MRS Seizure 
Lateralization from 
Absolute Asymmetry 
P01 Right 7 1-2 per mo. - [NAA], [Cr] Indeterminate 
P03 Left 4 1 per mo.  Glx/Cr [Glx] Left 
P08 Left 1 1 per mo. -  [Cr] Left 
P10 
Right Origin 
Seizures, 
Bilateral Spikes 
1 3 per yr.  Cho/Cr,  Myo/Cr 
[Cr], [Cho], 
[Myo], [Glx] 
Right 
P12 Left 28 1 per mo. - - - 
P13 Right 1 30 per mo. - [Cho] Right 
P14 Left 5 Sz Free for 1 yr. - [Cr] Right* 
P15 Right 2 4 per mo. - [Cho] Left* 
P16 Bilateral 8 4 per mo. - [Cr], [Myo] Right 
P17 Bilateral 10 7 per mo. - - - 
P18 Right 1 17 per mo.  NAA/Cr,  NAA/(Cr+ Cho) - - 
P19 Right 2 Sz Free for 2 yr.  Cho/Cr [Cr], [Cho] Left* 
P21 Right 1 1 per yr. - - - 
P22 Right 1 7 per yr. - - - 
P24 
Unknown, 
Bilateral Seizure 
Spread 
1 1 per yr. - - - 
P02 Right 2 1 per mo. Only One Spectrum Collected   
P04 Left 2 8 per mo. Only One Spectrum Collected   
P09 Bilateral 0.5 4 per yr. Only One Spectrum Collected   
P23 Bilateral 22 18 per mo. Only One Spectrum Collected   
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2.2.2 Seizure Lateralization 
Clinically established seizure lateralization was used in later analyses for 
classification of MRS spectra. This was determined for each patient as part of 
clinical treatment, primarily using interictal scalp EEG data and seizure 
semiology. Additional clinical information such as ictal and/or intracranial 
EEG was used for lateralization where available. 
2.2.3 MR Protocol 
Due to hardware and software upgrades performed on our 7T MR scanner, 
two different MR protocols were used over the course of this study. 
The first eight patients and eight healthy controls were scanned on a 7T 
Agilent/Siemens head-only MRI system using a 16 channel transmit and 
receive birdcage RF head coil (built in house).  T1-weighted images were 
collected using an MPRAGE sequence (TE = 2.22 ms, TR = 6.24 ms, voxel size 
0.59x0.43x1.00 mm) after global shimming. These images were later used for 
determining voxel placement. MRS data were acquired using a semi-LASER 
sequence (TE = 37.5 ms, TR = 3700 ms, 256 averages) from a 2.7x1.3x1.3 cm3 
voxel placed centrally over the hippocampus (See Figure 2.1, row A). This 
sequence interleaved a water suppressed metabolite spectrum with a 
metabolite nulled macromolecule spectrum [19], [20]. Metabolite nulling was 
achieved using a double inversion recovery preparation incorporating two 
non-selective 5ms adiabatic full passage (AFP) pulses to suppress metabolite 
signal [18]. Data were obtained from two separate voxels positioned to 
include the left and right hippocampi. From each voxel we acquired an 
unsuppressed water spectrum as an internal reference signal for 
quantification, a full spectrum containing all metabolite and macromolecule 
resonances using VAPOR water suppression [21], and the previously 
described macromolecule only spectrum.   
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Figure 2.1 – Hippocampal Voxel Placement: Image showing voxel placement for A) TE = 
37.5 ms acquisition overlaid on a 𝑇1 weighted MPRAGE image and B) a TE = 60 ms 
acquisition overlaid on a 𝑇1 weighted MP2RAGE image. For the TE= 37.5 ms acquisition, the 
MRS voxel was places along the cardinal axes of the MR system, whereas in the TE= 60 ms 
acquisition the voxel was placed at an oblique angle such that it followed the length of the 
hippocampus. 
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The remaining participants were scanned on a 7T Siemens head-only MRI 
system using a custom built head-only phased array composed of 8 transmit 
and 32 receive channels. T1-weighted images were collected using an 
MP2RAGE sequence (TE = 2.83 ms, TR = 8.3 ms, voxel size 0.75 mm  
isotropic). MRS data were collected using a semi-LASER sequence (TE = 60, 
TR = 7500, 64 averages) from a 2.7x1.3x1.3 cm3 voxel. This voxel was 
positioned obliquely along the long axis of the hippocampus (Figure 2.1, row 
B). From this voxel we acquired an unsuppressed water spectrum and a full 
spectrum containing metabolite and macromolecule resonances using VAPOR 
water suppression. This sequence did not incorporate an interleaved 
macromolecule only acquisition. 
2.2.4 Spectral Processing and Metabolite Quantification 
Metabolite levels were measured using custom software developed by our lab. 
All data first underwent a combination of QUALITY deconvolution, to restore 
peak Lorentzian lineshape, and eddy current correction. Residual water 
signals were removed by subtracting an automated Hankel singular value 
decomposition fit of the water peaks from the acquired spectrum [22], [23]. 
Metabolite lineshapes were simulated for each pulse sequence using custom 
software built with PyGamma [24], producing templates that were fitted to 
the in vivo data [25]. The macromolecule only spectra acquired from the 
healthy controls scanned with TE= 37.5 ms were averaged together to create 
a template for fitting the macromolecule component. This macromolecule 
lineshape was added to the prior knowledge templates for data acquired on 
both MRI systems. The in vivo data were then fitted to the simulated 
metabolite and macromolecule templates in the time domain using a 
Levenberg-Marquard minimization algorithm to determine the contribution 
of each metabolite to the in-vivo spectrum [23]. This fitting algorithm 
established the best possible fit by adjusting peak amplitude for each 
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metabolite, chemical shift and phase for 5 different groups of metabolites 
(See Table 2.2), and total spectral linewidth. In total, 14 metabolites were 
simulated and used to fit the in vivo spectrum; these were N-acetylaspartate 
(NAA), N-acetylaspartate glutamate, total creatine (Cr), total choline (Cho), 
lactate, myo-inositol (Myo), scyllo-inosotol, glutamate and glutamine 
(combined into the measure Glx), glutathione, taurine, glucose, glycine, 
phosphorylethanolamine, and 𝛾-aminobutyric acid. The concentration for 
each metabolite was calculated both as a ratio to Cr, and as an absolute 
concentration using the separately acquired water as an internal reference 
signal. In addition, NAA/(Cr+ Cho) was calculated for comparison with 
previous findings in the literature. 
Ratios to Cr were calculated by summing the peak amplitudes contributing to 
each metabolite lineshape, then dividing the normalized metabolite 
amplitude with that of Cr (see Equation 2.1): 
 
𝑋 𝐶𝑟⁄ =  
Σ𝑆𝐴𝑚𝑝,𝑋
Σ𝑆𝐴𝑚𝑝,𝐶𝑟
 
(2.1)  
where 𝑋 𝐶𝑟⁄  is the ratio of the metabolite of interest X to Cr, and Σ𝑆𝐴𝑚𝑝,𝑋 and 
Σ𝑆𝐴𝑚𝑝,𝐶𝑟 are the total amplitude of all peaks that form the spectral line shape 
of the metabolite of interest and Cr. 
Absolute metabolite levels, which provide average metabolite concentrations 
within the combined grey/white matter tissue fraction of voxel, were 
evaluated using the following expression (Equation 2.2): 
 
[𝑋]𝑇𝑖𝑠𝑠𝑢𝑒 =  
Σ𝑆𝐴𝑚𝑝,𝑋
Σ𝑆𝐴𝑚𝑝,𝐻2𝑂
 
𝑛𝜌,𝐻2𝑂
𝑛𝜌,𝑋
𝑅𝐻2𝑂
𝑅𝑋
∗ [𝐻2𝑂]𝑉𝑜𝑥𝑒𝑙 ∗ (𝐺𝑀 + 𝑊𝑀) 
(2.2)  
where [𝑋]𝑇𝑖𝑠𝑠𝑢𝑒 is the concentration of the metabolite of interest within the 
tissue fraction of the MRS voxel, Σ𝑆𝐴𝑚𝑝,𝑋 and Σ𝑆𝐴𝑚𝑝,𝐻2𝑂 are the sum of spectral 
peak amplitudes for the metabolite of interest and water respectively, 𝑛𝜌,𝑋 
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and 𝑛𝜌,𝐻2𝑂are the number of protons producing spectral signal for both the 
metabolite of interest and water, 𝑅𝑋 and 𝑅𝐻2𝑂 are corrections for the 
combined 𝑇1 and 𝑇2 relaxation of both the metabolite of interest and water 
(See Table 2.2),  [𝐻2𝑂]𝑉𝑜𝑥𝑒𝑙 is the average concentration of water within the 
voxel (based on GM/WM/CSF tissue fractions), and (𝐺𝑀 + 𝑊𝑀) is the voxel 
tissue fraction for grey and white matter [26]. 
In all cases, voxel tissue volume fractions were evaluated using the Oxford 
Centre for Functional MRI of the Brain (FMRIB) software library (FSL) [27]. 
Images were brain extracted using FSL's Brain Extraction Tool (BET)[28], 
while GM/ WM/ CSF voxel fractions were determined using the FMRIB 
Automated Segmentation Tool (FAST) [29]. Literature reported relaxation 
and water concentration values were used in Equation 2 (See Table 2.2) [30]–
[33]. 
2.2.5 Statistical Analysis 
Metabolites were excluded from analysis if the coefficient of variation (CV) of 
their absolute concentration within the healthy control group was greater 
than 35%. This was done to exclude both metabolites that were not reliably 
fit by the fitting algorithm, and to exclude metabolites with high variability 
within a healthy population. The metabolites with CVs below this threshold 
that were included in the subsequent group comparisons were NAA, Cho, Cr, 
Myo, and Glx. 
For group comparisons, both absolute and relative metabolite concentrations 
were compared between healthy controls, data from patient hippocampi 
ipsilateral to clinically established seizure focus, and data from patient 
hippocampi contralateral to seizure focus. This was accomplished using a 
pair of MANCOVA tests; one comparing absolute metabolite levels across 
groups, and the other comparing metabolite ratios. In each test, two 
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Metabolite 
Chemical Shift and 
Phase Group for Fit 
T1 Grey 
Matter (s) 
T2 Grey 
Matter (ms) 
T1 White 
Matter (s) 
T2 White 
Matter (ms) 
Source 
N-Acetylaspartate NAA 1.83 ±0.05 191 ± 7 1.90 ±0.06 164 ± 6 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
N-Acetylaspartyl 
Glutamate 
NAA 1.21 ± 0.22 191 ± 7 0.94 ± 0.08 164 ± 6 
T1 values from Marjanska et. Al. (2012); T2 assumed to be the 
same as N-Acetylaspartate 
Lactate NAA 1.28 ± 0.08 160 ± 20 1.19 ± 0.07 100 ± 15 Assumed same relaxation times as Myo-inositol 
Creatine (CH3) Cr 1.74 ± 0.06 131 ± 8 1.78 ± 0.04 113 ± 2 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Creatine (CH2+ NH) Cr 1.13 ± 0.04 102 ± 3 1.10 ± 0.06 108 ± 5 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Choline Cho 1.51 ± 0.11 200 ± 17 1.32 ± 0.06 139 ± 9 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Myo-inositol Myo 1.28 ± 0.08 160 ± 20 1.19 ± 0.07 100 ± 15 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Alanine Myo 1.28 ± 0.08 160 ± 20 1.19 ± 0.07 100 ± 15 Assumed same relaxation times as Myo-inositol 
Glucose Myo 1.28 ± 0.08 160 ± 20 1.19 ± 0.07 100 ± 15 Assumed same relaxation times as Myo-inositol 
Glycine Myo  1.28 ± 0.08 160 ± 20 1.19 ± 0.07 100 ± 15 Assumed same relaxation times as Myo-inositol 
Phosphoryl-
ethanolamine 
Myo 1.31 ± 0.18 160 ± 20 1.32 ±0.30 100 ± 15 
T1 values from Marjanska et. Al. (2012); T2 assumed to be the 
same as Myo-inositol 
Scyllo-inositol Myo 1.31 ± 0.20 130 ± 20 1.23 ± 0.07 112 ± 4 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Taurine Myo 2.15 ± 0.11 120 ± 20 2.09 ± 0.04 90 ± 16 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Glutamate Glu 1.61 ± 0.09 139 ± 8 1.75 ± 0.04 98 ± 4 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
Glutamine Glu 1.64 ± 0.07 139 ± 8 1.74 ± 0.23 98 ± 4 
T1 values from Marjanska et. Al. (2012), T2 assumed to be the 
same as Glutamate 
Glutathione Glu 1.14 ± 0.18 80 ± 10 1.06 ± 0.06 97 ± 8 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
GABA Glu 1.33 ± 0.16 87 ± 11 1.33 ± 0.16 87 ± 11 Andreychenko et. Al. (2013) 
Water 
Fit in separate 
water spectrum 
2.00 ± 0.12 48 ± 3 1.55 ± 0.07 47 ± 1 
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al. 
(2013) 
 
Table 2.2 – Metabolite Shift Groupings and 7T Relaxation Times used for Absolute Metabolite Quantification 
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covariates were used to correct for differences between pulse sequences; one 
was a categorical variable indicating which system was used to collect the 
data, and the other was voxel white matter content. White matter content 
was specifically added tot his analysis due to a significant difference in the 
white matter content between the different voxels used. Statistical analysis 
was performed in SPSS Statistics (IBM, version 25, 2017).  
To determine whether individual metabolites were associated with seizure 
lateralization, asymmetry indices were calculated for both metabolite ratios 
and absolute concentrations (Equation 2.3): 
 
𝐴𝐼 =  
[𝑋]𝐿𝑒𝑓𝑡 − [𝑋]𝑅𝑖𝑔ℎ𝑡
([𝑋]𝐿𝑒𝑓𝑡 + [𝑋]𝑅𝑖𝑔ℎ𝑡)/2
 
(2.3)  
where AI is the asymmetry index, and [𝑋]𝐿𝑒𝑓𝑡 and [𝑋]𝑅𝑖𝑔ℎ𝑡 are the 
concentrations of the metabolite of interest in the left and right hippocampi 
respectively [34]. To assess abnormality, the average AI and its standard 
deviation were calculated for the healthy control group. Patients were said to 
have abnormal asymmetry if their asymmetry index for a metabolite fell 
more than two standard deviations away from the control average. Seizure 
lateralization was made based on these observed asymmetry abnormalities, 
and the expected metabolite changes reported in the literature (ipsilaterally, 
NAA level was expected to decrease, Cho and Cr levels were expected to 
increase). Asymmetry indices that fell within two standard deviations of the 
control average were considered non-lateralizing. Average absolute z-scores 
were calculated to establish the mean absolute difference in asymmetry 
between patients and healthy controls.  
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2.3 Results 
2.3.1 Group Analysis 
A typical spectrum acquired from the hippocampus of one participant is 
provided in Figure 1.6 (pg. 29) along with the fitted metabolite components.  
In comparison to the primary NAA peak, MRS spectra had an average SNR= 
25.8± 8.2, while the average linewidth of the unsuppressed water peak was 
16.8± 3.4 Hz.  The average GM/WM/CSF fractions within hippocampal voxels 
were 58± 11%/36± 13%/5± 4% for the TE=37.5 ms data and 65± 5%/25± 
7%/10± 4% for the TE=60 ms data.  Average metabolite levels and ratios for 
control hippocampi, patient contralateral hippocampi, and patient ipsilateral 
hippocampi are provided in Table 2.3. For patients with bilateral TLE, both 
hippocampi were included in the ipsilateral group. When comparing healthy 
controls to ipsilateral hippocampi to contralateral hippocampi, the 
MANCOVA analysis showed a significant increase in [Cho] when comparing 
ipsilateral hippocampi to controls (p = 0.03). The MANCOVA did identify and 
correct for significant differences in the measured concentrations between the 
TE=37.5 and TE=60 ms pulse sequences; [NAA] was 20% higher in the TE= 
60 ms data, [Cho] was 17% lower in the TE= 60 ms data, [Glx] was 45% 
higher, NAA/Cr was 41% higher, Myo/Cr was 22% higher, Glx/Cr was 58% 
higher, and NAA/(Cr+Cho) was 40% higher.  
2.3.2 Asymmetry Analysis 
The results of the asymmetry analysis are summarized in Table 2.4. In 
patients, there was a high level of asymmetry (average |𝑧|= 1.76) in the 
absolute concentration of Cr in patients compared to healthy controls. When 
used to lateralize seizure focus, [Cr] increase correctly lateralized seizure 
focus in 3/12 patients with unilateral seizure focus while also meeting our 
abnormality criterion of >2 SD from healthy control mean in 1/3 patients 
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Measure 
Control 
Average and 
Standard 
Deviation 
Contralateral 
Patient Average 
and Standard 
Deviation 
Ipsilateral Patient 
Average and 
Standard 
Deviation 
Group 
Difference 
f-statistic  
Group 
Difference 
 p-value  
N-Acetylaspartate (mM) 11.4 ± 1.9 11.6 ± 3.0 11.5 ± 2.1 0.45 0.64 
Creatine (mM) 11.6 ± 1.5 11.9 ± 2.9 11.7 ± 2.5 1.84 0.17 
Choline (mM) 3.4 ± 0.5 3.5 ± 0.8 3.9 ± 1.0 3.60 0.03* 
Myo-inositol (mM) 6.7 ± 1.4 6.2 ± 2.2 6.8 ± 3.0 0.17 0.84 
Glx (mM) 9.8 ± 3.0 8.8 ± 5.9 9.2 ± 4.1 0.06 0.94 
NAA/Cr 1.08 ± 0.29 1.03 ± 0.31 1.06 ± 0.38 0.18 0.84 
Cho/Cr 0.96 ± 0.13 0.92 ± 0.09 1.00 ± 0.24 1.90 0.16 
Myo/Cr 0.80 ± 0.18 0.71 ± 0.24 0.82 ± 0.35 0.90 0.41 
Glx/Cr 0.84 ± 0.34 0.77 ± 0.47 0.82 ± 0.46 0.46 0.63 
NAA/(Cho+ Cr) 0.55 ± 0.14 0.53 ± 0.15 0.53 ± 0.17 0.39 0.68 
 
Table 2.3 – Metabolite Levels Within Subject Groups and p-values from MANCOVA Analysis: Average values are given without 
any corrections for co-varying factors, p-values given by main MANCOVA analyses 
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Measure 
Control 
Asymmetry 
Average Score 
Controls Outside 
2 Standard 
Deviations 
Patients with 
Ipsilat. Increase 
(>2 SD) 
Patients with 
Ipsilat. Decrease 
(>2 SD) 
Average Patient 
Absolute Z-Score 
N-Acetylaspartate (mM) -0.03 ± 0.22 1 1 0 0.79 
Creatine (mM) 0.16 ± 0.15 0 4 2 1.76 
Choline (mM) 0.15 ± 0.15 1 2 1 1.16 
Myo-inositol (mM) 0.20 ± 0.42 1 2 1 1.03 
Glx (mM) 0.35 ± 0.58 1 2 0 0.72 
NAA/Cr -0.20 ±0.23 1 0 1 0.72 
Cho/Cr -0.04 ±0.18 1 1 1 0.87 
Myo/Cr -0.01 ± 0.40 1 1 0 0.80 
Glx/Cr 0.23 ± 0.52 0 1 0 0.77 
NAA/(Cr+ Cho) -0.18 ± 0.21 1 0 1 0.83 
 
Table 2.4 – Average Metabolite Asymmetry Scores and Lateralization Results 
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with bilateral TLE (Table 2.1). The other metabolic metrics calculated had 
lower absolute z-scores and were not as successful at lateralizing seizure 
origin. For each of these measures, anomalous asymmetry only lateralized 
one or two of the unilateral patients.  
When lateralizing seizure focus using all observed metabolic change in a 
given subject, metabolite asymmetries successfully lateralized 4/12 unilateral 
TLE patients, with 3 incorrect lateralizations, and one indeterminate result. 
For the 4 bilateral TLE patients examined in this analysis, metabolite 
asymmetry gave an indeterminate result for one patient, and lateralized 
seizure focus to the right temporal lobe for another. 
2.4 Discussion 
In this study of non-lesional TLE, we identified a significant increase in the 
absolute level of Cho in ipsilateral hippocampi from non-lesional TLE 
patients compared to healthy controls. On an individual basis we found 
substantial variation in [Cr], which successfully lateralized 3/16 patients 
using our lateralization criteria of being more than two standard deviations 
from the mean control level. When corrected for the differences between pulse 
sequences, we found a significant change in [Cho] levels between groups. 
Comparing the mean values for [Cho], we see that there is an increase in 
[Cho] levels ipsilateral to seizure focus relative to control measurements. In 
the existing literature, changes in Cho have not been previously reported in 
non-lesional TLE. Increases in choline are associated with cellular membrane 
turnover, cell density, and gliosis [35], [36]; in studies of epilepsy Cho is 
commonly included in ratio quantities such as NAA/(Cho+Cr) to sensitize 
these metrics to increased gliosis, and choline changes have been previously 
reported by studies examining lesional TLE [2], [6], [10], [37]–[39]. The most 
common histological finding in MRI-normal TLE is nonspecific gliosis without 
neuronal damage or loss [2], [7]. With this in mind, our observed changes in 
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Cho appear to be in agreement with the existing literature, as the known 
prevalence on gliosis within this patient group is most likely to result in Cho 
increases [2], [39]. Meanwhile our results did not show a change in NAA 
levels, the most commonly reported change in the epileptic population [40], 
[41]. NAA change is typically associated with neuronal dysfunction or loss 
[18], [36], [42]. As this patient group histologically does not consistently show 
neuronal damage as in other epilepsies [2], [7], our lack of significant NAA 
change appears to be consistent with previous research.  
The observed variation of [Cr] is also noteworthy. Prior studies have reported 
metabolite levels as ratios to Cr either due to its assumed invariance between 
healthy and seizure forming tissue [36], or as a proposed functional measure 
where a combination of decreases in NAA and increases in Cr created a more 
powerful measure than the individual metabolites [39], [43]. Our results 
indicate that in non-lesional TLE absolute [Cr] and [Cho] levels may be more 
useful than metabolite ratios. While we do not see a consistent ipsilateral 
change in [Cr] levels between healthy and epileptic tissue, we do see 
substantial variation in [Cr] levels within patients that is not present in 
healthy controls. More concerning, this variance in Cr may mask significant 
changes in other metabolites; we found significant changes in absolute [Cho] 
levels in our group analysis, however this change was not observed in the 
Cho/Cr ratio.  
One potential factor accounting for the large variance of [Cr] without 
significant changes in the group analysis is the MRI-negative nature of the 
patient population. Given the lack of identifiable MRI changes and any 
histological information, the underlying pathology causing seizures in each 
patient is unknown. Histology has shown that MRI negative TLE is a 
heterogeneous group in terms of pathology [2]. It therefore follows that our 
patient population is heterogeneous in terms of underlying pathology and as 
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such we would expect patients to have differing metabolic abnormalities. 
When grouped together, these differing metabolic profiles could very easily 
average out to no significance, leading to our observed variations in [Cr].  
Spectroscopy data for this study were acquired using two different parameter 
sets for the semi-LASER sequence. Pulse sequence specific simulations were 
used to account for differences in the metabolite lineshapes arising from 
differences in echo times.  In the MANCOVA analysis, significant differences 
attributable to the pulse sequences used were found in [NAA], [Cho], [Glx], 
NAA/Cr, Myo/Cr, Glx/Cr, NAA/(Cr+Cho). These changes can be partially 
explained by the differing tissue fractions within the different voxels used. 
The concentrations calculated in our analysis are the average concentration 
of metabolites within the tissue component of our voxel, as CSF contains 
negligible metabolite levels, yet the concentration of various metabolites 
change between grey and white matter. Between our two pulse sequences, 
62% of the signal collected during the TE= 37.5 ms acquisition is from grey 
matter versus a grey matter contribution of 72% for the TE= 60 ms 
acquisition, with white matter contributing the remaining signal in both 
cases. NAA, Glu, Myo, and Cr all are present in higher concentrations in grey 
matter than white matter [18], [36], [44], while Cho levels are higher in white 
matter than cortical grey matter [45]. These results match with the 
variations identified by our MANCOVA analysis, where Cho is lower and 
other metabolites are higher in the TE=60 ms acquisition, with its higher 
grey matter component.  
Several other factors were not controlled for in this study. No corrections 
were made for the potential impact of anti-epileptic drugs on the MRS 
results. In addition, time since last seizure at time of scan was not tracked. 
Seizures have been shown to temporarily cause substantial variation in 
metabolite levels immediately post-seizure which persist for several hours 
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post-ictally, making time from last seizure a complicating factor, particularly 
when examining patients with frequent seizures [46].  
2.5 Conclusion 
From our analysis, it appears that choline and creatine, as measured 
independently from one another as absolute quantities, may be biomarkers 
for epileptic tissue in non-lesional TLE patients. While our results are in 
general agreement with the existing literature, additional and larger studies, 
ideally incorporating histological data when available, are necessary to 
establish the clinical utility of these measures.  
 70 
References 
[1] F. Al Sufiani and L. C. Ang, “Neuropathology of Temporal Lobe 
Epilepsy,” Epilepsy Res. Treat., vol. 2012, pp. 1–13, 2012. 
[2] W. Muhlhofer, Y. L. Tan, S. G. Mueller, and R. Knowlton, “MRI-
negative temporal lobe epilepsy—What do we know?,” Epilepsia, vol. 
58, no. 5, pp. 727–742, 2017. 
[3] T. Breyer et al., “Imaging of Patients with Hippocampal Sclerosis at 7 
Tesla. Initial Results,” Acad. Radiol., vol. 17, no. 4, pp. 421–426, 2010. 
[4] R. M. Wellard, R. S. Briellmann, J. W. Prichard, A. Syngeniotis, and G. 
D. Jackson, “Myoinositol abnormalities in temporal lobe epilepsy,” 
Epilepsia, vol. 44, no. 6, pp. 815–821, 2003. 
[5] R. J. Simister, M. A. McLean, G. J. Barker, and J. S. Duncan, “Proton 
magnetic resonance spectroscopy of malformations of cortical 
development causing epilepsy,” Epilepsy Res., vol. 74, no. 2–3, pp. 107–
115, 2007. 
[6] K. Ercan, H. P. Gunbey, E. Bilir, E. Zan, and H. Arslan, “Comparative 
Lateralizing Ability of Multimodality MRI in Temporal Lobe Epilepsy,” 
Dis. Markers, vol. 2016, 2016. 
[7] M. Y. Xu et al., “Proton MR Spectroscopy in Patients with Structural 
MRI-Negative Temporal Lobe Epilepsy,” J. Neuroimaging, vol. 25, no. 
6, pp. 1030–1037, 2015. 
[8] D. Wagnerová et al., “The Relationships Between Quantitative MR 
Parameters in Hippocampus in Healthy Subjects and Patients With 
Temporal Lobe Epilepsy,” Physiol. Res, vol. 64, pp. 407–417, 2015. 
[9] M. F. Chernov et al., “Role of proton magnetic resonance spectroscopy in 
preoperative evaluation of patients with mesial temporal lobe epilepsy,” 
J. Neurol. Sci., vol. 285, no. 1–2, pp. 212–219, 2009. 
[10] S. K. Lee, D. W. Kim, K. K. Kim, C. K. Chung, I. C. Song, and K. H. 
Chang, “Effect of seizure on hippocampus in mesial temporal lobe 
 71 
epilepsy and neocortical epilepsy: An MRS study,” Neuroradiology, vol. 
47, no. 12, pp. 916–923, 2005. 
[11] J. G. Burneo, R. C. Knowlton, E. Faught, R. Martin, S. Sawrie, and R. I. 
Kuzniecky, “Chronic temporal lobe epilepsy: Spatial extent and degree 
of metabolic dysfunction studied with magnetic resonance spectroscopy 
(MRS),” Epilepsy Res., vol. 62, no. 2–3, pp. 119–124, 2004. 
[12] S. G. Mueller et al., “Widespread extrahippocampal NAA/(Cr+Cho) 
abnormalities in TLE with and without mesial temporal sclerosis,” J. 
Neurol., vol. 258, no. 4, pp. 603–612, 2011. 
[13] J. . Shen, L. . Zhang, X. . Tian, J. . Liu, X. . Ge, and X. . Zhang, “Use of 
short echo time two-dimensional 1H-magnetic resonance spectroscopy 
in temporal lobe epilepsy with negative magnetic resonance imaging 
findings,” J. Int. Med. Res., vol. 37, no. 4, pp. 1211–1219, 2009. 
[14] M. T. Doelken et al., “1H-MRS profile in MRI positive- versus MRI 
negative patients with temporal lobe epilepsy,” Seizure, vol. 17, no. 6, 
pp. 490–497, 2008. 
[15] J. Suhy et al., “1H MRSI predicts surgical outcome in MRI-negative 
temporal lobe epilepsy,” Neurology, vol. 58, no. 5, pp. 821–823, 2002. 
[16] Q. Tan et al., “Quantitative MR spectroscopy reveals metabolic changes 
in the dorsolateral prefrontal cortex of patients with temporal lobe 
epilepsy,” Eur. Radiol., 2018. 
[17] J. Detour et al., “Metabolomic characterization of human hippocampus 
from drug-resistant epilepsy with mesial temporal seizure,” Epilepsia, 
vol. 59, no. 3, pp. 607–616, 2018. 
[18] R. A. DeGraaf, in vivo NMR Spectroscopy, 2nd ed. John Wiley & Sons, 
Ltd, 2007. 
[19] J. Penner and R. Bartha, “Semi-LASER 1 H MR spectroscopy at 7 Tesla 
in human brain: Metabolite quantification incorporating subject-specific 
macromolecule removal,” Magn. Reson. Med., vol. 74, no. 1, pp. 4–12, 
2015. 
 72 
[20] M. N. E. Kassem and R. Bartha, “Quantitative proton short-echo-time 
LASER spectroscopy of normal human white matter and hippocampus 
at 4 tesla incorporating macromolecule subtraction,” Magn. Reson. 
Med., vol. 49, no. 5, pp. 918–927, 2003. 
[21] I. Tkáč, Z. Starčuk, I. Y. Choi, and R. Gruetter, “In vivo 1H NMR 
spectroscopy of rat brain at 1 ms echo time,” Magn. Reson. Med., vol. 
41, no. 4, pp. 649–656, 1999. 
[22] R. Bartha, D. J. Drost, R. S. Menon, and P. C. Williamson, 
“Spectroscopic lineshape correction by QUECC: Combined QUALITY 
deconvolution and eddy current correction,” Magn. Reson. Med., vol. 44, 
no. 4, pp. 641–645, 2000. 
[23] R. Bartha, D. J. Drost, and P. C. Williamson, “Factors affecting the 
quantification of short echo in-vivo 1 H MR spectra : prior knowledge , 
peak elimination , and filtering,” pp. 205–216, 1999. 
[24] S. a. Smith, T. O. Levante, B. H. Meier, and R. R. Ernst, “Computer 
Simulations in Magnetic Resonance. An Object-Oriented Programming 
Approach,” J. Magn. Reson., Ser. A, vol. 106, no. 1. pp. 75–105, 1994. 
[25] D. Wong, A. Schranz, and R. Bartha, “Optimized in vivo brain 
glutamate measurement using long-echo-time semi-LASER at 7 T,” 
NMR Biomed., 2018. 
[26] R. Rupsingh, M. Borrie, M. Smith, J. L. Wells, and R. Bartha, “Reduced 
hippocampal glutamate in Alzheimer disease,” Neurobiol. Aging, vol. 
32, no. 5, pp. 802–810, 2011. 
[27] M. Jenkinson, C. F. Beckmann, T. E. J. Behrens, M. W. Woolrich, and 
S. M. Smith, “Fsl,” Neuroimage, vol. 62, no. 2, pp. 782–790, 2012. 
[28] Y. Zhang, M. Brady, and S. Smith, “Segmentation of brain MR images 
through a hidden Markov random field model and the expectation-
maximization algorithm,” IEEE Trans. Med. Imaging, vol. 20, no. 1, pp. 
45–57, 2001. 
[29] S. M. Smith, “Fast robust automated brain extraction,” Hum. Brain 
 73 
Mapp., vol. 17, no. 3, pp. 143–155, 2002. 
[30] M. Marjańska, E. J. Auerbach, R. Valabrègue, P. F. Van de Moortele, G. 
Adriany, and M. Garwood, “Localized 1H NMR spectroscopy in different 
regions of human brain in vivo at 7T: T 2 relaxation times and 
concentrations of cerebral metabolites,” NMR Biomed., vol. 25, no. 2, 
pp. 332–339, 2012. 
[31] L. Xin, B. Schaller, V. Mlynarik, H. Lu, and R. Gruetter, “Proton T1 
relaxation times of metabolites in human occipital white and gray 
matter at 7 T,” Magn. Reson. Med., vol. 69, no. 4, pp. 931–936, 2013. 
[32] A. Andreychenko, D. W. J. Klomp, R. A. De Graaf, P. R. Luijten, and V. 
O. Boer, “In vivo GABA T2determination with J-refocused echo time 
extension at 7 T,” NMR Biomed., vol. 26, no. 11, pp. 1596–1601, 2013. 
[33] R. Kreis, J. Slotboom, L. Hofmann, and C. Boesch, “Integrated data 
acquisition and processing to determine metabolite contents, relaxation 
times, and macromolecule baseline in single examinations of individual 
subjects,” Magn. Reson. Med., vol. 54, no. 4, pp. 761–768, 2005. 
[34] Y. Aitouche, S. A. Gibbs, G. Gilbert, O. Boucher, A. Bouthillier, and D. 
K. Nguyen, “Proton MR Spectroscopy in Patients with Nonlesional 
Insular Cortex Epilepsy Confirmed by Invasive EEG Recordings,” J. 
Neuroimaging, vol. 27, no. 5, pp. 517–523, 2017. 
[35] J. A. Mendes-Ribeiro, R. Soares, F. Simões-Ribeiro, and M. L. 
Guimarães, “Reduction in temporal N-acetylaspartate and creatine (or 
choline) ratio in temporal lobe epilepsy: Does this1H-magnetic 
resonance spectroscopy finding mean poor seizure control?,” J. Neurol. 
Neurosurg. Psychiatry, vol. 65, no. 4, pp. 518–522, 1998. 
[36] C. D. Rae, “A guide to the metabolic pathways and function of 
metabolites observed in human brain1H magnetic resonance spectra,” 
Neurochem. Res., vol. 39, no. 1, pp. 1–36, 2014. 
[37] K. N. Fountas, I. Tsougos, E. D. Gotsis, S. Giannakodimos, J. R. Smith, 
and E. Z. Kapsalaki, “Temporal pole proton preoperative magnetic 
 74 
resonance spectroscopy in patients undergoing surgery for mesial 
temporal sclerosis,” Neurosurg. Focus, vol. 32, no. 3, p. E3, 2012. 
[38] J. P. Ranjeva, S. Confort-Gouny, Y. Le Fur, and P. J. Cozzone, 
“Magnetic resonance spectroscopy of brain in epilepsy,” Child’s Nerv. 
Syst., vol. 16, no. 4, pp. 235–241, 2000. 
[39] J. W. Pan and R. I. Kuzniecky, “Utility of magnetic resonance 
spectroscopic imaging for human epilepsy.,” Quant. Imaging Med. 
Surg., vol. 5, no. 2, pp. 313–22, 2015. 
[40] J. W. Pan et al., “7T MR spectroscopic imaging in the localization of 
surgical epilepsy,” Epilepsia, vol. 54, no. 9, pp. 1668–1678, 2013. 
[41] F. Cendes, “Neuroimaging in investigation of patients with epilepsy.,” 
Continuum (Minneap. Minn)., vol. 19, pp. 623–42, 2013. 
[42] R. Kuzniecky et al., “Magnetic resonance spectroscopic imaging in 
temporal lobe epilepsy - Neuronal dysfunction or cell loss?,” Arch. 
Neurol., vol. 58, no. 12, pp. 2048–2053, 2001. 
[43] B. Maton, F. Gilliam, S. Sawrie, E. Faught, J. Hugg, and R. Kuzniecky, 
“Correlation of scalp EEG and 1H-MRS metabolic abnormalities in 
temporal lobe epilepsy,” Epilepsia, vol. 42, no. 3, pp. 417–422, 2001. 
[44] J. W. Pan, T. Venkatraman, K. Vives, and D. D. Spencer, “Quantitative 
glutamate spectroscopic imaging of the human hippocampus,” NMR 
Biomed., vol. 19, no. 2, pp. 209–216, 2006. 
[45] P. J. W. Pouwels and J. Frahm, “Regional metabolite concentrations in 
human brain as determined by quantitative localized proton MRS,” 
Magn. Reson. Med., vol. 39, no. 1, pp. 53–60, 1998. 
[46] F. Fadaie et al., “1H-MRS metabolite’s ratios show temporal alternation 
in temporal lobe seizure: Comparison between interictal and postictal 
phases,” Epilepsy Res., vol. 128, pp. 158–162, 2016. 
 75 
 
 
 
 
Chapter 3 
Conclusion and Future Work 
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3.1 Conclusions 
In this thesis, we aimed to detect metabolite level changes in epileptic tissue 
using high field magnetic resonance spectroscopy (MRS) in non-lesional TLE 
patients. To this end, we performed the first single-voxel MRS measurements 
at a magnetic field strength of 7T in this cohort.  
We found that average absolute choline and creatine concentrations were 
altered in non-lesional TLE patients compared to healthy controls. Similar 
variations were not found in the commonly used measures NAA/Cr and 
NAA/(Cr + Cho). The demonstrated alterations were consistent with pre-
existing knowledge about non-lesional TLE, suggesting these two metabolites 
were noteworthy candidates for future metabolic imaging studies. However, 
levels of these metabolites were not sufficiently different to be useful in 
seizure lateralization.  
There are two primary factors that could be contributing to this poor 
lateralization ability. Firstly, due to the MRI-normal nature of this patient 
population we do not have a clear picture of the underlying pathology; 
differing pathologies would have different metabolic effects, causing the 
significant but inconsistent changes seen in our results. Furthermore, there 
is likely a combination of healthy and epileptogenic tissue within our chosen 
voxel, in varying amounts in each patient. Given that concentration is 
measured as an average in all the tissue in a voxel, this would dilute any 
metabolic asymmetries our chosen measurement technique could identify in 
these patients. Lowering our criteria for determining significant asymmetry 
could help correct for this partial volume effect. However, lowering the 
significance threshold also increases the risk that non-pathologic variances in 
metabolite levels, created either by normal variance in metabolite levels, or 
by variance in the grey matter/white matter composition of our voxel, would 
give incorrect seizure lateralization. Another noteworthy confounding factor 
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for Cho in particular in this regard is diet; Cho levels within the brain are 
sensitive to the Cho content of food eaten and time since last meal, and 
dietary Cho fluctuations could be obscuring Cho changes due to epilepsy [1]. 
In this thesis, we had hoped to demonstrate the clinical utility of 7T MRS. 
While our conclusions were complicated by changes in scanner hardware and 
software over the course of our study, based on the data obtained in this 
study, it does not appears that 7T MRS of the hippocampus in TLE patients 
provides effective seizure lateralization in the majority of patients. The 
metabolic changes we detected occurred in metabolites that are readily 
identifiable at lower field strength. With that said, 7T systems have 
demonstrated advantages in identifying small lesions in ‘non-lesional’ 
epilepsy cases [2], and they may have an advantage when performing MRSI 
or other metabolic imaging techniques which were beyond the scope of this 
thesis. 
3.2 Future Work 
The work presented in this thesis could be meaningfully expanded in a 
number of different ways.  
The significant variations in metabolite levels did not provide good 
lateralization ability in our study. To clearly identify if [Cho] and [Cr] levels 
are clinically useful in seizure localization, the various confounding factors 
discussed above should be addressed. To avoid the specificity issues noted 
with a single voxel measurement, MRSI or other metabolic imaging 
measurements studying the behaviour of these metabolites as absolute 
concentrations are needed, as none currently exist in the literature. 
Performing such studies at a field strength of 7T could provide the spectral 
and spatial resolution needed to identify small epileptic foci which elude 
accurate characterization by single voxel techniques. Ideally, such studies 
would be paired whenever possible with histopathology of the underlying 
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tissue, to more clearly identify which metabolites are affected under differing 
pathologies.  
A number of animal studies have shown that Cho dietary supplementation 
has a neuroprotective effect in rodent models of epilepsy [3]. In light of the 
Cho changes we have identified, a rodent study that uses MRS to study Cho 
level change in rodents pre- and post-epileptogenesis with differing levels of 
dietary Cho could provide useful information on the behaviour of Cho in 
epilepsy. We found no studies examining the effects of dietary Cho 
supplementation in the human epileptic population. While a human study 
examining the effects of dietary choline would be challenging to carry out, if 
Cho has the same neuroprotective effect in humans as seen in animal models, 
it could be used to improve the quality of life of intractable epilepsy patients 
by reducing the cognitive decline seen in these patients.  
In the existing literature on epilepsy, very few studies examine the dynamic 
changes in MRS metabolite levels; the only study found in our review of the 
literature examining this was a small study of 5 patients [4]. Establishing the 
clinical utility of MRS requires that any variation in metabolite levels are 
known and can be controlled for, thus more and larger studies examining 
post-ictal metabolite changes are needed.  
This leads into a common problem with epilepsy studies as a whole; the 
general lack of large scale, multi-centre studies makes it difficult to 
demonstrate the clinical utility of MRS in epilepsy. Given that dozens of 
smaller scale studies conducted over 3 decades have demonstrated that there 
are metabolic changes occurring in the epileptic population, and that 
metabolic changes are associated with seizure focus, such a study could 
provide a powerful case for clinical use of MRS techniques. 
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